Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17174058,flow-rate,"The analysis was carried out on an ACQUITY UPLC BEH C(18) column (50 mm x 2.1 mm, i.d., 1.7 microm) with gradient elution at a flow-rate of 0.35 ml/min.",Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174058/),[ml] / [min],0.35,1393,DB00381,Amlodipine
,25575509,flow rate,"The mobile phase consisted of 0.1% formic acid in ammonium acetate buffer (0.02 M, pH 3.5) and methanol (25:75, v/v), flowing through XBridge BEH (50 × 2.1 mm ID, 5 µm) C18 column, at a flow rate of 0.6 mL min(-1).","Simultaneous Determination of Aliskiren Hemifumarate, Amlodipine Besylate and Hydrochlorothiazide in Spiked Human Plasma Using UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25575509/),[ml] / [min],0.6,2283,DB00381,Amlodipine
excess,1587055,t 1/2 beta,Amlodipine is an exception with a t 1/2 beta in excess of 30h.,Clinical pharmacokinetics of calcium antagonists. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587055/),h,30,2483,DB00381,Amlodipine
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,35,3347,DB00381,Amlodipine
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,50,3348,DB00381,Amlodipine
,16640453,protein binding,Ranolazine protein binding is about 61-64% over the therapeutic concentration range.,Clinical pharmacokinetics of ranolazine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,61-64,3349,DB00381,Amlodipine
,16640453,Volume of distribution at steady state,Volume of distribution at steady state ranges from 85 to 180 L.,Clinical pharmacokinetics of ranolazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),l,85 to 180,3350,DB00381,Amlodipine
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,1.4-1.9,3351,DB00381,Amlodipine
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,7,3352,DB00381,Amlodipine
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],45,3353,DB00381,Amlodipine
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],33,3354,DB00381,Amlodipine
,26558434,AUC(0-72),Mean (SD) AUC(0-72) was 102.7 (26.8) (26.8) μg × h/L for the solution and 108.2 (30.6) μg × h/L for the tablet.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[h·μg] / [l],102.7,5450,DB00381,Amlodipine
,26558434,AUC(0-72),Mean (SD) AUC(0-72) was 102.7 (26.8) (26.8) μg × h/L for the solution and 108.2 (30.6) μg × h/L for the tablet.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[h·μg] / [l],108.2,5451,DB00381,Amlodipine
,26558434,Cmax,Mean (SD) Cmax of the solution was 3.11(1.06) μg/L with a median (IQR) t(max) of 4.0 (2.6 - 7.5) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[μg] / [l],3.11,5452,DB00381,Amlodipine
,26558434,t(max),Mean (SD) Cmax of the solution was 3.11(1.06) μg/L with a median (IQR) t(max) of 4.0 (2.6 - 7.5) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),h,4.0,5453,DB00381,Amlodipine
,26558434,C(max),Mean (SD) C(max) of the tablet was 2.91 (0.84) μg/L with a median (IQR) tmax of 6.0 (4.0 - 14.0) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[μg] / [l],2.91,5454,DB00381,Amlodipine
,26558434,tmax,Mean (SD) C(max) of the tablet was 2.91 (0.84) μg/L with a median (IQR) tmax of 6.0 (4.0 - 14.0) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),h,6.0,5455,DB00381,Amlodipine
,2142447,elimination half-life,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,58,6787,DB00381,Amlodipine
,2142447,elimination half-life,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,42,6788,DB00381,Amlodipine
,2142447,clearance,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),[l] / [h],19,6789,DB00381,Amlodipine
,2142447,clearance,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),[l] / [h],25,6790,DB00381,Amlodipine
,2142447,half-life,"After a 3-months oral treatment washout period, half-life tended to be prolonged in the elderly patients (69 +/- 20 hours for the elderly patients versus 53 +/- 14 hours for the young patients; difference not significant) and was not markedly different from the short-term intravenous measurement.","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,69,6791,DB00381,Amlodipine
,2142447,half-life,"After a 3-months oral treatment washout period, half-life tended to be prolonged in the elderly patients (69 +/- 20 hours for the elderly patients versus 53 +/- 14 hours for the young patients; difference not significant) and was not markedly different from the short-term intravenous measurement.","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,53,6792,DB00381,Amlodipine
,22278138,concentrations,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [ml],2,7405,DB00381,Amlodipine
,22278138,tissue,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],29.0,7406,DB00381,Amlodipine
,22278138,tissue,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],107.3,7407,DB00381,Amlodipine
,22278138,concentrations,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],29.0,7408,DB00381,Amlodipine
,22278138,concentrations,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],107.3,7409,DB00381,Amlodipine
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],9.6,9523,DB00381,Amlodipine
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],13.7,9524,DB00381,Amlodipine
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],34.3,9525,DB00381,Amlodipine
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],43.9,9526,DB00381,Amlodipine
,8310971,elimination half-life,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 vs 42 +/- 8 hr; p < 0.05) caused by decreased clearance (19 +/- 5 vs 7 liters/hr; p < 0.05).",An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310971/),h,58,9592,DB00381,Amlodipine
,8310971,elimination half-life,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 vs 42 +/- 8 hr; p < 0.05) caused by decreased clearance (19 +/- 5 vs 7 liters/hr; p < 0.05).",An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310971/),h,42,9593,DB00381,Amlodipine
,8310971,clearance,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 vs 42 +/- 8 hr; p < 0.05) caused by decreased clearance (19 +/- 5 vs 7 liters/hr; p < 0.05).",An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310971/),[l] / [h],19,9594,DB00381,Amlodipine
,8310971,clearance,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 vs 42 +/- 8 hr; p < 0.05) caused by decreased clearance (19 +/- 5 vs 7 liters/hr; p < 0.05).",An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310971/),[l] / [h],7,9595,DB00381,Amlodipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,3,9816,DB00381,Amlodipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,10,9817,DB00381,Amlodipine
,9126675,elimination half-lives,"The onset of action of verapamil, nifedipine, and diltiazem, at least in immediate-release formulations, is relatively fast (0.5-2 hours), and their elimination half-lives range from 2 to 7 hours.",Pharmacological aspects of calcium channel blockers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),h,2 to 7,9818,DB00381,Amlodipine
longer,24132705,Tmax,"Meanwhile, the Cmax of amlodipine, losartan and EXP3174 were reduced by 11.4%, 20.0% and 41.4%, and the Tmax of losartan and EXP3174 were 1.3 and 1.8 h longer, respectively.",The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24132705/),h,1.3,15630,DB00381,Amlodipine
longer,24132705,Tmax,"Meanwhile, the Cmax of amlodipine, losartan and EXP3174 were reduced by 11.4%, 20.0% and 41.4%, and the Tmax of losartan and EXP3174 were 1.3 and 1.8 h longer, respectively.",The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24132705/),h,1.8,15631,DB00381,Amlodipine
,11069440,systemic availability,Oral amlodipine had high systemic availability (grapefruit juice: 88%; water: 81%).,Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069440/),%,88,17350,DB00381,Amlodipine
,11069440,systemic availability,Oral amlodipine had high systemic availability (grapefruit juice: 88%; water: 81%).,Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069440/),%,81,17351,DB00381,Amlodipine
,11069440,CL,"Total plasma clearance and volume of distribution, calculated after intravenous amlodipine, were essentially unchanged by grapefruit juice (CL 6.65 ml min-1 kg-1, juice vs 6.93 ml min-1 kg-1, water; Vdss 22.7 l kg-1, juice vs 21.0 l kg-1, water).",Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069440/),[ml] / [kg·min],6.65,17352,DB00381,Amlodipine
,11069440,CL,"Total plasma clearance and volume of distribution, calculated after intravenous amlodipine, were essentially unchanged by grapefruit juice (CL 6.65 ml min-1 kg-1, juice vs 6.93 ml min-1 kg-1, water; Vdss 22.7 l kg-1, juice vs 21.0 l kg-1, water).",Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069440/),[ml] / [kg·min],6.93,17353,DB00381,Amlodipine
,11069440,Vdss,"Total plasma clearance and volume of distribution, calculated after intravenous amlodipine, were essentially unchanged by grapefruit juice (CL 6.65 ml min-1 kg-1, juice vs 6.93 ml min-1 kg-1, water; Vdss 22.7 l kg-1, juice vs 21.0 l kg-1, water).",Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069440/),[l] / [kg],22.7,17354,DB00381,Amlodipine
,11069440,Vdss,"Total plasma clearance and volume of distribution, calculated after intravenous amlodipine, were essentially unchanged by grapefruit juice (CL 6.65 ml min-1 kg-1, juice vs 6.93 ml min-1 kg-1, water; Vdss 22.7 l kg-1, juice vs 21.0 l kg-1, water).",Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069440/),[l] / [kg],21.0,17355,DB00381,Amlodipine
,1387475,terminal elimination half life,The most notable pharmacokinetic features were a prolonged terminal elimination half life of 48 +/- 16 hours and a delayed tmax of 7.3 +/- 1.3 hours.,An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387475/),h,48,18649,DB00381,Amlodipine
,1387475,tmax,The most notable pharmacokinetic features were a prolonged terminal elimination half life of 48 +/- 16 hours and a delayed tmax of 7.3 +/- 1.3 hours.,An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387475/),h,7.3,18650,DB00381,Amlodipine
,24672114,relative bioavailabilities,"The mean (SD) relative bioavailabilities, as represented by AUC0-∞, of amlodipine and benazeprilat for tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively.","Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672114/),,1.060,19576,DB00381,Amlodipine
,24672114,relative bioavailabilities,"The mean (SD) relative bioavailabilities, as represented by AUC0-∞, of amlodipine and benazeprilat for tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively.","Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672114/),,0.949,19577,DB00381,Amlodipine
,16869811,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was significantly lower in subjects with 2677TT/3435TT (140.8 +/- 35.6 ng h(-1) ml(-1)) and 2677GT/3435CT (149.8 +/- 40.1 ng h(-1) ml(-1)) than in those with 2677GG/3435CC (208.6 +/- 39.2 ng h(-1) ml(-1)) [95% confidence interval (CI) on the difference, 2677GG/3435CC vs. 2677GT/3435CT 12.0, 105.6, P < 0.01; 2677GG/3435CC vs. 2677TT/3435TT 19.6, 116.0, P < 0.01; 2677GT/3435CT vs. 2677TT/3435TT - 39.2, 57.2, P > 0.05].",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [h·ml],140.8,19872,DB00381,Amlodipine
,16869811,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was significantly lower in subjects with 2677TT/3435TT (140.8 +/- 35.6 ng h(-1) ml(-1)) and 2677GT/3435CT (149.8 +/- 40.1 ng h(-1) ml(-1)) than in those with 2677GG/3435CC (208.6 +/- 39.2 ng h(-1) ml(-1)) [95% confidence interval (CI) on the difference, 2677GG/3435CC vs. 2677GT/3435CT 12.0, 105.6, P < 0.01; 2677GG/3435CC vs. 2677TT/3435TT 19.6, 116.0, P < 0.01; 2677GT/3435CT vs. 2677TT/3435TT - 39.2, 57.2, P > 0.05].",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [h·ml],149.8,19873,DB00381,Amlodipine
,16869811,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was significantly lower in subjects with 2677TT/3435TT (140.8 +/- 35.6 ng h(-1) ml(-1)) and 2677GT/3435CT (149.8 +/- 40.1 ng h(-1) ml(-1)) than in those with 2677GG/3435CC (208.6 +/- 39.2 ng h(-1) ml(-1)) [95% confidence interval (CI) on the difference, 2677GG/3435CC vs. 2677GT/3435CT 12.0, 105.6, P < 0.01; 2677GG/3435CC vs. 2677TT/3435TT 19.6, 116.0, P < 0.01; 2677GT/3435CT vs. 2677TT/3435TT - 39.2, 57.2, P > 0.05].",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [h·ml],208.6,19874,DB00381,Amlodipine
,16869811,peak plasma concentrations,"The peak plasma concentrations were highest in subjects with 2677GG/3435CC (3.8 +/- 0.5 ng ml(-1)), lower in subjects with 2677GT/3435CT (3.2 +/- 0.5 ng ml(-1)) and 2677TT/3435TT (2.7 +/- 0.5 ng ml(-1)) in rank and showed a significant difference between those with 2677GG/3435CC and with 2677TT/3435TT (95% CI on the difference 0.4, 2.0, P < 0.01).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [ml],3.8,19875,DB00381,Amlodipine
,16869811,peak plasma concentrations,"The peak plasma concentrations were highest in subjects with 2677GG/3435CC (3.8 +/- 0.5 ng ml(-1)), lower in subjects with 2677GT/3435CT (3.2 +/- 0.5 ng ml(-1)) and 2677TT/3435TT (2.7 +/- 0.5 ng ml(-1)) in rank and showed a significant difference between those with 2677GG/3435CC and with 2677TT/3435TT (95% CI on the difference 0.4, 2.0, P < 0.01).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [ml],3.2,19876,DB00381,Amlodipine
,16869811,peak plasma concentrations,"The peak plasma concentrations were highest in subjects with 2677GG/3435CC (3.8 +/- 0.5 ng ml(-1)), lower in subjects with 2677GT/3435CT (3.2 +/- 0.5 ng ml(-1)) and 2677TT/3435TT (2.7 +/- 0.5 ng ml(-1)) in rank and showed a significant difference between those with 2677GG/3435CC and with 2677TT/3435TT (95% CI on the difference 0.4, 2.0, P < 0.01).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [ml],2.7,19877,DB00381,Amlodipine
,16869811,oral clearance,"However, the oral clearance was higher in subjects with 2677TT/3435TT (37.7 +/- 10.2 l h(-1)) than in those with 2677GT/3435CT (35.7 +/- 9.9 l h(-1)) and with 2677GG/3435CC (24.8 +/- 5.4 l h(-1)) and exhibited a significant difference between ABCB1 genotype groups (95% CI on the difference, 2677GG/3435CC vs. 2677GT/3435CT - 21.5, - 0.3, P < 0.05; 2677GG/3435CC vs. 2677TT/3435TT - 23.8, - 2.0, P < 0.05).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[l] / [h],37.7,19878,DB00381,Amlodipine
,16869811,oral clearance,"However, the oral clearance was higher in subjects with 2677TT/3435TT (37.7 +/- 10.2 l h(-1)) than in those with 2677GT/3435CT (35.7 +/- 9.9 l h(-1)) and with 2677GG/3435CC (24.8 +/- 5.4 l h(-1)) and exhibited a significant difference between ABCB1 genotype groups (95% CI on the difference, 2677GG/3435CC vs. 2677GT/3435CT - 21.5, - 0.3, P < 0.05; 2677GG/3435CC vs. 2677TT/3435TT - 23.8, - 2.0, P < 0.05).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[l] / [h],35.7,19879,DB00381,Amlodipine
,16869811,oral clearance,"However, the oral clearance was higher in subjects with 2677TT/3435TT (37.7 +/- 10.2 l h(-1)) than in those with 2677GT/3435CT (35.7 +/- 9.9 l h(-1)) and with 2677GG/3435CC (24.8 +/- 5.4 l h(-1)) and exhibited a significant difference between ABCB1 genotype groups (95% CI on the difference, 2677GG/3435CC vs. 2677GT/3435CT - 21.5, - 0.3, P < 0.05; 2677GG/3435CC vs. 2677TT/3435TT - 23.8, - 2.0, P < 0.05).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[l] / [h],24.8,19880,DB00381,Amlodipine
,11526962,ED50,The ED50 value of AML against clonic seizures induced by PTZ was 5.4 mg/kg.,Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11526962/),[mg] / [kg],5.4,20652,DB00381,Amlodipine
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,4.5,21462,DB00381,Amlodipine
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,8.5,21463,DB00381,Amlodipine
,27795624,time to first increase in dose,Mean time to first increase in dose was 6.5 ± 3.6 days.,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),d,6.5,21464,DB00381,Amlodipine
,29559771,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) and the area under the plasma concentration-time curve from time 0 to the last measurement (AUC0-t) values of telmisartan were 522.29 ng/mL and 2,475.16 ng·h/mL for the FDC, and 540.45 ng/mL and 2,559.57 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[ng] / [ml],522.29,24839,DB00381,Amlodipine
,29559771,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) and the area under the plasma concentration-time curve from time 0 to the last measurement (AUC0-t) values of telmisartan were 522.29 ng/mL and 2,475.16 ng·h/mL for the FDC, and 540.45 ng/mL and 2,559.57 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[ng] / [ml],540.45,24840,DB00381,Amlodipine
,29559771,area under the plasma concentration-time curve from time 0 to the last measurement (AUC0-t),"The mean peak plasma concentration (Cmax) and the area under the plasma concentration-time curve from time 0 to the last measurement (AUC0-t) values of telmisartan were 522.29 ng/mL and 2,475.16 ng·h/mL for the FDC, and 540.45 ng/mL and 2,559.57 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[h·ng] / [ml],"2,475.16",24841,DB00381,Amlodipine
,29559771,area under the plasma concentration-time curve from time 0 to the last measurement (AUC0-t),"The mean peak plasma concentration (Cmax) and the area under the plasma concentration-time curve from time 0 to the last measurement (AUC0-t) values of telmisartan were 522.29 ng/mL and 2,475.16 ng·h/mL for the FDC, and 540.45 ng/mL and 2,559.57 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[h·ng] / [ml],"2,559.57",24842,DB00381,Amlodipine
,29559771,Cmax,"The mean Cmax and AUC0-t values of S-amlodipine were 2.71 ng/mL and 130.69 ng·h/mL for the FDC, and 2.74 ng/mL and 129.81 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[ng] / [ml],2.71,24843,DB00381,Amlodipine
,29559771,Cmax,"The mean Cmax and AUC0-t values of S-amlodipine were 2.71 ng/mL and 130.69 ng·h/mL for the FDC, and 2.74 ng/mL and 129.81 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[ng] / [ml],2.74,24844,DB00381,Amlodipine
,29559771,AUC0-t,"The mean Cmax and AUC0-t values of S-amlodipine were 2.71 ng/mL and 130.69 ng·h/mL for the FDC, and 2.74 ng/mL and 129.81 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[h·ng] / [ml],130.69,24845,DB00381,Amlodipine
,29559771,AUC0-t,"The mean Cmax and AUC0-t values of S-amlodipine were 2.71 ng/mL and 130.69 ng·h/mL for the FDC, and 2.74 ng/mL and 129.81 ng·h/mL for the individual agents concomitantly administered, respectively.",Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559771/),[h·ng] / [ml],129.81,24846,DB00381,Amlodipine
,32432949,Cmax,"Results: Curcumin significantly increased the Cmax (26.19 ± 2.21 versus 17.80 ± 1.56 μg/L), AUC(0-t) (507.27 ± 60.23 versus 238.68 ± 45.59 μg·h/L), and t1/2 (14.69 ± 1.64 versus 11.43 ± 1.20 h) of amlodipine (p < 0.05).",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),[μg] / [l],26.19,25784,DB00381,Amlodipine
,32432949,Cmax,"Results: Curcumin significantly increased the Cmax (26.19 ± 2.21 versus 17.80 ± 1.56 μg/L), AUC(0-t) (507.27 ± 60.23 versus 238.68 ± 45.59 μg·h/L), and t1/2 (14.69 ± 1.64 versus 11.43 ± 1.20 h) of amlodipine (p < 0.05).",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),[μg] / [l],17.80,25785,DB00381,Amlodipine
,32432949,AUC(0-t),"Results: Curcumin significantly increased the Cmax (26.19 ± 2.21 versus 17.80 ± 1.56 μg/L), AUC(0-t) (507.27 ± 60.23 versus 238.68 ± 45.59 μg·h/L), and t1/2 (14.69 ± 1.64 versus 11.43 ± 1.20 h) of amlodipine (p < 0.05).",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),[h·μg] / [l],507.27,25786,DB00381,Amlodipine
,32432949,AUC(0-t),"Results: Curcumin significantly increased the Cmax (26.19 ± 2.21 versus 17.80 ± 1.56 μg/L), AUC(0-t) (507.27 ± 60.23 versus 238.68 ± 45.59 μg·h/L), and t1/2 (14.69 ± 1.64 versus 11.43 ± 1.20 h) of amlodipine (p < 0.05).",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),[h·μg] / [l],238.68,25787,DB00381,Amlodipine
,32432949,t1/2,"Results: Curcumin significantly increased the Cmax (26.19 ± 2.21 versus 17.80 ± 1.56 μg/L), AUC(0-t) (507.27 ± 60.23 versus 238.68 ± 45.59 μg·h/L), and t1/2 (14.69 ± 1.64 versus 11.43 ± 1.20 h) of amlodipine (p < 0.05).",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),h,14.69,25788,DB00381,Amlodipine
,32432949,t1/2,"Results: Curcumin significantly increased the Cmax (26.19 ± 2.21 versus 17.80 ± 1.56 μg/L), AUC(0-t) (507.27 ± 60.23 versus 238.68 ± 45.59 μg·h/L), and t1/2 (14.69 ± 1.64 versus 11.43 ± 1.20 h) of amlodipine (p < 0.05).",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),h,11.43,25789,DB00381,Amlodipine
,32432949,half-life time,"The metabolic stability of amlodipine was significantly increased with the half-life time in rat liver microsomes increased from 34.23 ± 3.33 to 44.15 ± 4.12 min, and the intrinsic rate decreased from 40.49 ± 3.26 to 31.39 ± 2.78 μL/min/mg protein.",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),min,34.23,25790,DB00381,Amlodipine
,32432949,half-life time,"The metabolic stability of amlodipine was significantly increased with the half-life time in rat liver microsomes increased from 34.23 ± 3.33 to 44.15 ± 4.12 min, and the intrinsic rate decreased from 40.49 ± 3.26 to 31.39 ± 2.78 μL/min/mg protein.",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),min,44.15,25791,DB00381,Amlodipine
,32432949,intrinsic rate,"The metabolic stability of amlodipine was significantly increased with the half-life time in rat liver microsomes increased from 34.23 ± 3.33 to 44.15 ± 4.12 min, and the intrinsic rate decreased from 40.49 ± 3.26 to 31.39 ± 2.78 μL/min/mg protein.",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),[μl] / [mg·min],40.49,25792,DB00381,Amlodipine
,32432949,intrinsic rate,"The metabolic stability of amlodipine was significantly increased with the half-life time in rat liver microsomes increased from 34.23 ± 3.33 to 44.15 ± 4.12 min, and the intrinsic rate decreased from 40.49 ± 3.26 to 31.39 ± 2.78 μL/min/mg protein.",Effects of curcumin on the pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32432949/),[μl] / [mg·min],31.39,25793,DB00381,Amlodipine
,25750535,peak plasma concentration,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),[ng] / [ml],1.66-23.06,29970,DB00381,Amlodipine
,25750535,time to peak plasma concentration,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),h,2.6-4.0,29971,DB00381,Amlodipine
,25750535,area under the plasma concentration versus time curve from time 0 hour to 96 hours,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),[ng] / [h·ml],17.9-429,29972,DB00381,Amlodipine
,25750535,elimination half-life,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),h,16.0-28.0,29973,DB00381,Amlodipine
,22947502,flow rate,"Reverse-phase high performance liquid chromatography (RP-HPLC) separation was accomplished on a Diamonsil C(18) column (50mm×4.6mm, 5μm) with a mobile phase composed of methanol-water-formic acid (75:25:0.01, v/v/v) at a flow rate of 0.3mL/min.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),[ml] / [min],0.3,33867,DB00381,Amlodipine
,22947502,total run time,The method had a chromatographic total run time of 3min.,Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),min,3,33868,DB00381,Amlodipine
,22947502,m/,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,409,33869,DB00381,Amlodipine
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,326.2,33870,DB00381,Amlodipine
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,116.0,33871,DB00381,Amlodipine
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,277.0,33872,DB00381,Amlodipine
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,203.0,33873,DB00381,Amlodipine
,2467122,half-life,"It is water soluble and photostable, and has a long half-life of 35-50 h.",Pharmacokinetics of calcium antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467122/),h,35-50,33986,DB00381,Amlodipine
,28888975,imprinting factors,"Applying the LF model for the binding isotherm, imprinting factors was 2.80 for the LC-MIP with the crosslinking degree of 20.0%, whereas 6.70 for the LC-free MIP with high levels of crosslinker (80.0%).",Solvent-responsive floating liquid crystalline-molecularly imprinted polymers for gastroretentive controlled drug release system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888975/),,2.80,34483,DB00381,Amlodipine
,28888975,imprinting factors,"Applying the LF model for the binding isotherm, imprinting factors was 2.80 for the LC-MIP with the crosslinking degree of 20.0%, whereas 6.70 for the LC-free MIP with high levels of crosslinker (80.0%).",Solvent-responsive floating liquid crystalline-molecularly imprinted polymers for gastroretentive controlled drug release system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888975/),,6.70,34484,DB00381,Amlodipine
>,28888975,gastric residence time,In vivo imaging experiment proved that the floating LC-MIP had significantly longer gastric residence time (>60min) than the non-floating MIP reference (<30min).,Solvent-responsive floating liquid crystalline-molecularly imprinted polymers for gastroretentive controlled drug release system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888975/),min,60,34485,DB00381,Amlodipine
<,28888975,gastric residence time,In vivo imaging experiment proved that the floating LC-MIP had significantly longer gastric residence time (>60min) than the non-floating MIP reference (<30min).,Solvent-responsive floating liquid crystalline-molecularly imprinted polymers for gastroretentive controlled drug release system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888975/),min,30,34486,DB00381,Amlodipine
,28888975,relative bioavailability,"In spite of lower imprinting factor, the relative bioavailability of the gastro-floating LC-MIP was 180.5%, whereas only 111.7% of the LC-free MIP.",Solvent-responsive floating liquid crystalline-molecularly imprinted polymers for gastroretentive controlled drug release system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888975/),%,180.5,34487,DB00381,Amlodipine
,28888975,relative bioavailability,"In spite of lower imprinting factor, the relative bioavailability of the gastro-floating LC-MIP was 180.5%, whereas only 111.7% of the LC-free MIP.",Solvent-responsive floating liquid crystalline-molecularly imprinted polymers for gastroretentive controlled drug release system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888975/),%,111.7,34488,DB00381,Amlodipine
,15922817,compliance rates,"Compliance rates were similar between groups, with mean (SD) compliance rates of 97.4% (2.8%) and 97.1% (3.6%) in the amlodipine maleate and amlodipine besylate groups, respectively.","Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15922817/),%,97.4,43817,DB00381,Amlodipine
,15922817,compliance rates,"Compliance rates were similar between groups, with mean (SD) compliance rates of 97.4% (2.8%) and 97.1% (3.6%) in the amlodipine maleate and amlodipine besylate groups, respectively.","Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15922817/),%,97.1,43818,DB00381,Amlodipine
,16400709,AUC(0-6 h),"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC(0-6 h) of amlodipine was significantly greater than the controls (34.5+/-6.01 compared with 28.0+/-4.70 microg min/ml), indicating that amlodipine is metabolized via CYP3A1/2 in rats.","Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400709/),[min·μg] / [ml],34.5,43866,DB00381,Amlodipine
,16400709,AUC(0-6 h),"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC(0-6 h) of amlodipine was significantly greater than the controls (34.5+/-6.01 compared with 28.0+/-4.70 microg min/ml), indicating that amlodipine is metabolized via CYP3A1/2 in rats.","Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400709/),[min·μg] / [ml],28.0,43867,DB00381,Amlodipine
,29385884,Cmax,"The results indicated that when the rats were pre-treated with triptolide, the Cmax of amlodipine increased from 13.78 ± 3.57 to 19.96 ± 4.56 ng/mL (p < 0.05), the Tmax increased from 4.04 ± 1.15 to 5.89 ± 1.64 h (p < 0.05), and the AUC0-t increased by approximately 104% (p < 0.05), which suggested that the pharmacokinetic behaviour of amlodipine was affected after oral co-administration of triptolide.",Effects of triptolide on pharmacokinetics of amlodipine in rats by using LC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385884/),[ng] / [ml],13.78,46789,DB00381,Amlodipine
,29385884,Cmax,"The results indicated that when the rats were pre-treated with triptolide, the Cmax of amlodipine increased from 13.78 ± 3.57 to 19.96 ± 4.56 ng/mL (p < 0.05), the Tmax increased from 4.04 ± 1.15 to 5.89 ± 1.64 h (p < 0.05), and the AUC0-t increased by approximately 104% (p < 0.05), which suggested that the pharmacokinetic behaviour of amlodipine was affected after oral co-administration of triptolide.",Effects of triptolide on pharmacokinetics of amlodipine in rats by using LC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385884/),[ng] / [ml],19.96,46790,DB00381,Amlodipine
,29385884,Tmax,"The results indicated that when the rats were pre-treated with triptolide, the Cmax of amlodipine increased from 13.78 ± 3.57 to 19.96 ± 4.56 ng/mL (p < 0.05), the Tmax increased from 4.04 ± 1.15 to 5.89 ± 1.64 h (p < 0.05), and the AUC0-t increased by approximately 104% (p < 0.05), which suggested that the pharmacokinetic behaviour of amlodipine was affected after oral co-administration of triptolide.",Effects of triptolide on pharmacokinetics of amlodipine in rats by using LC-MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385884/),h,4.04,46791,DB00381,Amlodipine
,29385884,Tmax,"The results indicated that when the rats were pre-treated with triptolide, the Cmax of amlodipine increased from 13.78 ± 3.57 to 19.96 ± 4.56 ng/mL (p < 0.05), the Tmax increased from 4.04 ± 1.15 to 5.89 ± 1.64 h (p < 0.05), and the AUC0-t increased by approximately 104% (p < 0.05), which suggested that the pharmacokinetic behaviour of amlodipine was affected after oral co-administration of triptolide.",Effects of triptolide on pharmacokinetics of amlodipine in rats by using LC-MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385884/),h,5.89,46792,DB00381,Amlodipine
,29385884,metabolic half-life,"Additionally, the metabolic half-life was prolonged from 22.5 ± 4.26 to 36.8 ± 6.37 min (p < 0.05) with the pre-treatment of triptolide.",Effects of triptolide on pharmacokinetics of amlodipine in rats by using LC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385884/),min,22.5,46793,DB00381,Amlodipine
,29385884,metabolic half-life,"Additionally, the metabolic half-life was prolonged from 22.5 ± 4.26 to 36.8 ± 6.37 min (p < 0.05) with the pre-treatment of triptolide.",Effects of triptolide on pharmacokinetics of amlodipine in rats by using LC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385884/),min,36.8,46794,DB00381,Amlodipine
,1666430,half-life,"Of these agents, amlodipine has by far the longest half-life (30-40 h) allowing the benefit of once-daily administration; it has the additional property of a slow association and dissociation with the calcium channel binding site.",Profiles of calcium antagonists in cardiovascular disease with special reference to second-generation agents and amlodipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1666430/),h,30-40,47183,DB00381,Amlodipine
,32034814,maximum plasma concentration (Cmax ),"In fasting subjects, the maximum plasma concentration (Cmax ) was 3.881 ± 0.982 ng/mL at 6 hours (median) of sponsor T, and 4.042 ± 1.147 ng/mL at 6 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],3.881,47709,DB00381,Amlodipine
,32034814,maximum plasma concentration (Cmax ),"In fasting subjects, the maximum plasma concentration (Cmax ) was 3.881 ± 0.982 ng/mL at 6 hours (median) of sponsor T, and 4.042 ± 1.147 ng/mL at 6 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],4.042,47710,DB00381,Amlodipine
,32034814,Cmax,"In fed subjects, Cmax was 3.312 ± 0.789 ng/mL at 6 hours (median) of sponsor T, and 3.392 ± 0.902 ng/mL at 5 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],3.312,47711,DB00381,Amlodipine
,32034814,Cmax,"In fed subjects, Cmax was 3.312 ± 0.789 ng/mL at 6 hours (median) of sponsor T, and 3.392 ± 0.902 ng/mL at 5 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],3.392,47712,DB00381,Amlodipine
,12579861,flow-rate,"The mobile phase consisted of acetonitrile-water-formic acid (75:35:1), at a flow-rate of 0.4 mL.min-1.",[Determination of amlodipine in human plasma by liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579861/),[ml] / [min],0.4,48172,DB00381,Amlodipine
,22472448,V/V,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),,3.5,48975,DB00381,Amlodipine
,22472448,flow rate,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),[ml] / [min],1,48976,DB00381,Amlodipine
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,76.5,48977,DB00381,Amlodipine
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,72.0,48978,DB00381,Amlodipine
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,73.0,48979,DB00381,Amlodipine
,22235096,maximum tolerated dose,The maximum tolerated dose was 8.5 mg/m(2) but escalation to 14 mg/m(2) was possible with only temporary reversible cerebrovascular toxicity by excluding hypertensive patients.,Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235096/),[mg] / [m],8.5,51913,DB00381,Amlodipine
,15282762,run time,The chromatographic run time was 1.5 min and the weighted (1/x(2)) calibration curves were linear over the range 0.1-25 ng ml(-1).,"Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),min,1.5,52957,DB00381,Amlodipine
,15282762,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 50 and 100 pg ml(-1), respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),[pg] / [ml],50,52958,DB00381,Amlodipine
,15282762,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 50 and 100 pg ml(-1), respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),[pg] / [ml],100,52959,DB00381,Amlodipine
,15282762,absolute recoveries,"The average absolute recoveries of lacidipine and amlodipine (IS) from spiked plasma samples were 51.1 +/- 1.3 and 50.3 +/- 4.9%, respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),%,51.1,52960,DB00381,Amlodipine
,15282762,absolute recoveries,"The average absolute recoveries of lacidipine and amlodipine (IS) from spiked plasma samples were 51.1 +/- 1.3 and 50.3 +/- 4.9%, respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),%,50.3,52961,DB00381,Amlodipine
,24666338,activated partial th,"Eleven hours post overdose extracorporeal elimination was implemented as the patient developed worsening coagulopathy with an elevated international normalized ratio of 11 IU, an activated partial thromboplastin time of 115 s, and had renal impairment with a creatinine of 158 μmol/L.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),s,115,53236,DB00381,Amlodipine
,24666338,peak serum dabigatran level,"This patient developed a peak serum dabigatran level of 1560 ng/ml, 11 h postoverdose.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ng] / [ml],1560,53237,DB00381,Amlodipine
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],58.1,53238,DB00381,Amlodipine
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],31.9,53239,DB00381,Amlodipine
,24666338,extraction ratio,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),,0.2,53240,DB00381,Amlodipine
,2943308,plasma half-life,"Intravenous administration of amlodipine (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 ml min-1 kg-1 and a mean apparent volume of distribution of 21 l kg-1.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),h,34,57282,DB00381,Amlodipine
,2943308,clearance,"Intravenous administration of amlodipine (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 ml min-1 kg-1 and a mean apparent volume of distribution of 21 l kg-1.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),[ml] / [kg·min],7,57283,DB00381,Amlodipine
,2943308,apparent volume of distribution,"Intravenous administration of amlodipine (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 ml min-1 kg-1 and a mean apparent volume of distribution of 21 l kg-1.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),[l] / [kg],21,57284,DB00381,Amlodipine
,2943308,systemic availability,"Oral administration (single dose, 10 mg) to the same 12 volunteers gave a mean systemic availability of 64% and a mean plasma half-life of 36 h.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),%,64,57285,DB00381,Amlodipine
,2943308,plasma half-life,"Oral administration (single dose, 10 mg) to the same 12 volunteers gave a mean systemic availability of 64% and a mean plasma half-life of 36 h.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),h,36,57286,DB00381,Amlodipine
,2943308,half-life,"In a second study, repeated oral administration (once daily for 14 days, 15 mg) to 28 volunteers resulted in steady state plasma drug concentration being reached after seven doses, an accumulation of approximately threefold and a mean half-life of 45 h.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),h,45,57287,DB00381,Amlodipine
,26997703,flow rate,"The bioanalytical method was developed in rat plasma by using Thermo beta-basic C18 (100×4.6 mm, 5 μm) and mobile phase was composed of dibasic phosphate buffer (pH 3.0):acetonitrile in the ratio of 55:45 at a flow rate of 1 ml/min with ultraviolet detection monitored at 240 nm.",Development of Validated Bioanalytical HPLC-UV Method for Simultaneous Estimation of Amlodipine and Atorvastatin in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26997703/),[ml] / [min],1,59711,DB00381,Amlodipine
more,26997703,recovery,The mean recovery (%) was more than 92.8% for both the drugs using protein precipitation method.,Development of Validated Bioanalytical HPLC-UV Method for Simultaneous Estimation of Amlodipine and Atorvastatin in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26997703/),%,92.8,59712,DB00381,Amlodipine
,25853070,flow rate,"Chromatographic separation of amlodipine and valsartan was achieved on the Luna C18 (2)100A (150 × 4.6 mm, 5 μm) column using acetonitrile: 5 mM ammonium formate solution (80:20, v/v) as the mobile phase at a flow rate of 0.8 mL/min in isocratic mode.",Development and Validation of a LC-MS/MS Method for the Simultaneous Estimation of Amlodipine and Valsartan in Human Plasma: Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853070/),[ml] / [min],0.8,61019,DB00381,Amlodipine
,19277959,total run time,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),min,2.8,63151,DB00381,Amlodipine
,19277959,flow rate,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),[ml] / [min],0.50,63152,DB00381,Amlodipine
,15351061,flow rate,The mobile phase was sodium phosphate buffer (pH 2.5) containing 1 ml/l triethylamine and methanol at flow rate of 2.8 ml/min.,Simple and rapid HPLC method for determination of amlodipine in human serum with fluorescence detection and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15351061/),[ml] / [min],2.8,63960,DB00381,Amlodipine
,20171424,AUC(0-last),The mean (SD) AUC(0-last) was 129.7 (62.8) ng . h/mL after dosing with S-amlodipine and 129.0 (59.6) ng . h/mL after dosing with amlodipine racemate.,"Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171424/),[h·ng] / [ml],129.7,65497,DB00381,Amlodipine
,20171424,AUC(0-last),The mean (SD) AUC(0-last) was 129.7 (62.8) ng . h/mL after dosing with S-amlodipine and 129.0 (59.6) ng . h/mL after dosing with amlodipine racemate.,"Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171424/),[h·ng] / [ml],129.0,65498,DB00381,Amlodipine
,21923441,absorption rate constant,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),1/[hour],1.28,66359,DB00381,Amlodipine
,21923441,clearance,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),[l] / [h],43.6,66360,DB00381,Amlodipine
,21923441,apparent volume of distribution,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),l,1990,66361,DB00381,Amlodipine
,19593736,m/,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,338.3,71595,DB00381,Amlodipine
,19593736,m/,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,78.0,71596,DB00381,Amlodipine
,19593736,m/z,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,407.3,71597,DB00381,Amlodipine
,19593736,m/z,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,295.5,71598,DB00381,Amlodipine
within,19593736,total run time,"The method showed a dynamic linearity range from 10.4 to 2045.0 ng/mL, lower limit of quantitation achieved at 10.4 ng/mL and finally a mass spectrometric total run time of within 2.5 min for human sample analysis.",Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),min,2.5,71599,DB00381,Amlodipine
,19593736,half-life matching,"The challenge of half-life matching for test and reference drug was achieved with 73.43 +/- 9.68 and 73.06 +/- 14.03 h, respectively, and intra-subject coefficient of variation achieved within 11% for AUCs and C(max) evaluated by non-compartmental pharmacokinetic analysis.",Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),h,73.43,71600,DB00381,Amlodipine
,19593736,half-life matching,"The challenge of half-life matching for test and reference drug was achieved with 73.43 +/- 9.68 and 73.06 +/- 14.03 h, respectively, and intra-subject coefficient of variation achieved within 11% for AUCs and C(max) evaluated by non-compartmental pharmacokinetic analysis.",Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),h,73.06,71601,DB00381,Amlodipine
,16400620,pKa,"More unionized fractions of amlodipine could exist in less acidic conditions of gastrointestinal fluids, since amlodipine is a weak basic drug with pKa of 8.7.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),,8.7,71959,DB00381,Amlodipine
,16400620,"total area under the plasma concentration-time curve from time zero to the last measured time, 48 h","For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),[h·ng] / [ml],725,71960,DB00381,Amlodipine
,16400620,"total area under the plasma concentration-time curve from time zero to the last measured time, 48 h","For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),[h·ng] / [ml],348,71961,DB00381,Amlodipine
,16400620,Tmax,"For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),h,1.50,71962,DB00381,Amlodipine
,16400620,Tmax,"For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),h,5.00,71963,DB00381,Amlodipine
,31060428,Cmax,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[ng] / [ml],16.25,73205,DB00381,Amlodipine
,31060428,Cmax,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[ng] / [ml],22.79,73206,DB00381,Amlodipine
,31060428,AUC(0-t),"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[gh·n] / [ml],222.87,73207,DB00381,Amlodipine
,31060428,AUC(0-t),"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[gh·n] / [ml],468.32,73208,DB00381,Amlodipine
,31060428,t1/2,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),h,10.60,73209,DB00381,Amlodipine
,31060428,t1/2,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),h,14.15,73210,DB00381,Amlodipine
,31060428,metabolic stability,The metabolic stability of ALDP was also decreased (23.6 ± 4.7 vs. 38.9 ± 5.2) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),,23.6,73211,DB00381,Amlodipine
,31060428,metabolic stability,The metabolic stability of ALDP was also decreased (23.6 ± 4.7 vs. 38.9 ± 5.2) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),,38.9,73212,DB00381,Amlodipine
,8933429,limit of detection,The quantitative assay shows linearity over the range 0.5-10 ng ml-1 for the two enantiomers and the limit of detection is about 0.2 ng ml-1.,Coupled-column chromatography on a Chiral-AGP phase for determination of amlodipine enantiomers in human plasma: an HPLC assay with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933429/),[ng] / [ml],0.2,75207,DB00381,Amlodipine
,20629042,flow rate,"The reconstituted samples were chromatographed on C(18) column by pumping 0.1% formic acid-acetonitrile (15:85, v/v) at a flow rate of 1 mL/min.","Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),[ml] / [min],1,77437,DB00381,Amlodipine
,20629042,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,"Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),min,2.5,77438,DB00381,Amlodipine
,2153819,IC50,"One of the compounds, 2-[[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6- methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]acetamide (26, UK-51,656), was identified as a potent (IC50 = 4 x 10(-9) M) calcium antagonist which is 20-fold selective for vascular over cardiac tissue and which has a markedly longer duration of action (greater than 5 h) than nifedipine in the anesthetized dog on intravenous administration.","Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153819/),M,4 x 10(-9),78543,DB00381,Amlodipine
,2153819,half-life,The pharmacokinetic half-life of 26 was established as 4.7 h and possible explanations are advanced to account for 26 having a shorter plasma half-life than amlodipine and a longer plasma half-life than felodipine.,"Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153819/),h,4.7,78544,DB00381,Amlodipine
,16397912,linear dynamic,"The assay exhibited a linear dynamic range of 50-10,000 pg/mL for amlodipine in human plasma.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),[pg] / [ml],"50-10,000",79752,DB00381,Amlodipine
,16397912,absolute recoveries,"The average absolute recoveries of amlodipine and the IS from spiked plasma samples were 74.7 +/- 4.6 and 72.1 +/- 2.0%, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),%,74.7,79753,DB00381,Amlodipine
,16397912,absolute recoveries,"The average absolute recoveries of amlodipine and the IS from spiked plasma samples were 74.7 +/- 4.6 and 72.1 +/- 2.0%, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),%,72.1,79754,DB00381,Amlodipine
,16397912,run time,A run time of 1.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),min,1.5,79755,DB00381,Amlodipine
,16397912,observed maximum plasma concentration (Cmax),"The observed maximum plasma concentration (Cmax) of amlodipine (2.5 mg oral dose) was 1425 pg/mL, time to observed maximum plasma concentration (Tmax) was 8.1 h and elimination half-life (T(1/2)) was 50.1 h.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),[pg] / [ml],1425,79756,DB00381,Amlodipine
,16397912,time to observed maximum plasma concentration (Tmax),"The observed maximum plasma concentration (Cmax) of amlodipine (2.5 mg oral dose) was 1425 pg/mL, time to observed maximum plasma concentration (Tmax) was 8.1 h and elimination half-life (T(1/2)) was 50.1 h.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),h,8.1,79757,DB00381,Amlodipine
,16397912,elimination half-life (T(1/2)),"The observed maximum plasma concentration (Cmax) of amlodipine (2.5 mg oral dose) was 1425 pg/mL, time to observed maximum plasma concentration (Tmax) was 8.1 h and elimination half-life (T(1/2)) was 50.1 h.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),h,50.1,79758,DB00381,Amlodipine
,2459525,concentrations,Mean (+/- SD) digoxin concentrations of 0.64 +/- 0.19 ng/ml after 2-week digoxin monotherapy and 0.61 +/- 0.23 ng/ml during placebo were not altered by amlodipine (0.60 +/- 0.18 mg/ml).,Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459525/),[ng] / [ml],0.,82344,DB00381,Amlodipine
,2459525,Renal digoxin clearance,Renal digoxin clearance was 202 +/- 44 ml/min on placebo and 207 +/- 55 ml/min during amlodipine coadministration.,Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459525/),[ml] / [min],202,82345,DB00381,Amlodipine
,2459525,Renal digoxin clearance,Renal digoxin clearance was 202 +/- 44 ml/min on placebo and 207 +/- 55 ml/min during amlodipine coadministration.,Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459525/),[ml] / [min],207,82346,DB00381,Amlodipine
,26006182,elimination half-life,Amlodipine elimination half-life during the first MARS™ session was calculated at 7.6 h.,Mixed amlodipine/valsartan overdose treated by the molecular adsorbent recirculating system (MARS™). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006182/),h,7.6,84289,DB00381,Amlodipine
,11185633,maximum plasma concentration (Cmax),"The geometric means of the primary pharmacokinetic parameters at steady state (day 9) for amlodipine when given alone were the following: maximum plasma concentration (Cmax) 17.7 ng/mL, area under the plasma concentration-time curve (AUC) 331 ng.h/mL, and renal clearance 39.5 mL/min, with 8% of the total amlodipine dose being excreted.",Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185633/),[ng] / [ml],17.7,84368,DB00381,Amlodipine
,11185633,area under the plasma concentration-time curve (AUC),"The geometric means of the primary pharmacokinetic parameters at steady state (day 9) for amlodipine when given alone were the following: maximum plasma concentration (Cmax) 17.7 ng/mL, area under the plasma concentration-time curve (AUC) 331 ng.h/mL, and renal clearance 39.5 mL/min, with 8% of the total amlodipine dose being excreted.",Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185633/),[h·ng] / [ml],331,84369,DB00381,Amlodipine
,11185633,renal clearance,"The geometric means of the primary pharmacokinetic parameters at steady state (day 9) for amlodipine when given alone were the following: maximum plasma concentration (Cmax) 17.7 ng/mL, area under the plasma concentration-time curve (AUC) 331 ng.h/mL, and renal clearance 39.5 mL/min, with 8% of the total amlodipine dose being excreted.",Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185633/),[ml] / [min],39.5,84370,DB00381,Amlodipine
,2467130,Bioavailability,"Bioavailability of unchanged drug after oral administration was high with values of 63, 88, 100, and 100% in humans, dogs, mice, and rats, respectively.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),%,63,87599,DB00381,Amlodipine
,2467130,Bioavailability,"Bioavailability of unchanged drug after oral administration was high with values of 63, 88, 100, and 100% in humans, dogs, mice, and rats, respectively.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),%,88,87600,DB00381,Amlodipine
,2467130,Bioavailability,"Bioavailability of unchanged drug after oral administration was high with values of 63, 88, 100, and 100% in humans, dogs, mice, and rats, respectively.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),%,100,87601,DB00381,Amlodipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,35,87602,DB00381,Amlodipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,2,87603,DB00381,Amlodipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,30,87604,DB00381,Amlodipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,3,87605,DB00381,Amlodipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,11,87606,DB00381,Amlodipine
,31556335,peak plasma concentration,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[ng] / [ml],18.28,87978,DB00381,Amlodipine
,31556335,peak plasma concentration,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[ng] / [ml],24.13,87979,DB00381,Amlodipine
,31556335,oral clearance,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[l] / [h·kg],4.57,87980,DB00381,Amlodipine
,31556335,oral clearance,The results showed that atorvastatin could significantly increase the peak plasma concentration (from 18.28 ± 2.65 to 24.13 ± 1.96 ng/mL) and decrease the oral clearance (from 4.57 ± 1.15 to 1.79 ± 0.28 L/h/kg) of ALDP.,Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[l] / [h·kg],1.79,87981,DB00381,Amlodipine
,31556335,intrinsic clearance rate,"In the rat liver microsome systems, the intrinsic clearance rate of ALDP was decreased by the pretreatment with atorvastatin (39.26 ± 2.1 vs. 33.24 ± 3.3 μL/min/mg protein).",Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[μl] / [mg·min],39.26,87982,DB00381,Amlodipine
,31556335,intrinsic clearance rate,"In the rat liver microsome systems, the intrinsic clearance rate of ALDP was decreased by the pretreatment with atorvastatin (39.26 ± 2.1 vs. 33.24 ± 3.3 μL/min/mg protein).",Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556335/),[μl] / [mg·min],33.24,87983,DB00381,Amlodipine
,19041284,retention times,The retention times of isradipine (0.81 min) and IS (0.65 min) suggested the potential for high throughput of the proposed method.,Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041284/),min,0.81,88570,DB00381,Amlodipine
,19041284,retention times,The retention times of isradipine (0.81 min) and IS (0.65 min) suggested the potential for high throughput of the proposed method.,Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041284/),min,0.65,88571,DB00381,Amlodipine
,16296697,absolute bioavailability,Amlodipine is absorbed gradually after oral administration (peak plasma levels 6-12 h postdose) and has an absolute bioavailability of 64%.,Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16296697/),%,64,95655,DB00381,Amlodipine
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB00381,Amlodipine
,9156957,pKa,A pKa value of 8.7 means that amlodipine is predominantly present in the ionized form at a physiologic pH.,Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156957/),,8.7,96632,DB00381,Amlodipine
,33706186,extraction recovery,"The average extraction recovery of perindopril, perindoprilat and indapamide samples at low, medium, and high concentration levels were between 85.9% and 93.6%, respectively.","Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33706186/),%,85.9,97193,DB00381,Amlodipine
,33706186,extraction recovery,"The average extraction recovery of perindopril, perindoprilat and indapamide samples at low, medium, and high concentration levels were between 85.9% and 93.6%, respectively.","Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33706186/),%,93.6,97194,DB00381,Amlodipine
,25343287,time to maximum plasma concentration (tmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),h,2.6,98438,DB00381,Amlodipine
,25343287,time to maximum plasma concentration (tmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),h,4.1,98439,DB00381,Amlodipine
,25343287,time to maximum plasma concentration (tmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),h,8.3,98440,DB00381,Amlodipine
,25343287,time to maximum plasma concentration (tmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),h,8.9,98441,DB00381,Amlodipine
,25343287,maximum plasma concentration (Cmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [ml],278.5,98442,DB00381,Amlodipine
,25343287,maximum plasma concentration (Cmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [ml],212.4,98443,DB00381,Amlodipine
,25343287,maximum plasma concentration (Cmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [ml],232.1,98444,DB00381,Amlodipine
,25343287,maximum plasma concentration (Cmax,"Oral administration of amlodipine produced an increase of time to maximum plasma concentration (tmax: 2.6, 4.1, 8.3, and 8.9 h at 0, 0.5, 1, and 2 g/kg/d, respectively), and a decrease of maximum plasma concentration (Cmax: 278.5, 212.4, 232.1, and 238.7 ng/ml at 0, 0.5, 1, and 2 g/kg/d, respectively.).",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [ml],238.7,98445,DB00381,Amlodipine
,25343287,area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h,"However, the area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h was 3487.4, 2895.4, 3158.2, and 3495 ng/h/ml at 0, 0.5, 1, and 2 g/kg/d respectively) was not significantly changed among the different dose groups.",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [h·ml],3487.4,98446,DB00381,Amlodipine
,25343287,area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h,"However, the area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h was 3487.4, 2895.4, 3158.2, and 3495 ng/h/ml at 0, 0.5, 1, and 2 g/kg/d respectively) was not significantly changed among the different dose groups.",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [h·ml],2895.4,98447,DB00381,Amlodipine
,25343287,area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h,"However, the area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h was 3487.4, 2895.4, 3158.2, and 3495 ng/h/ml at 0, 0.5, 1, and 2 g/kg/d respectively) was not significantly changed among the different dose groups.",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [h·ml],3158.2,98448,DB00381,Amlodipine
,25343287,area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h,"However, the area under the concentration-time curve from time 0 to 24 h measurable concentration (AUC0-24 h was 3487.4, 2895.4, 3158.2, and 3495 ng/h/ml at 0, 0.5, 1, and 2 g/kg/d respectively) was not significantly changed among the different dose groups.",Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25343287/),[ng] / [h·ml],3495,98449,DB00381,Amlodipine
,17517538,flow rate,The flow rate was set at 1.5 ml/min.,"Validated HPLC method for the determination of gabapentin in human plasma using pre-column derivatization with 1-fluoro-2,4-dinitrobenzene and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517538/),[ml] / [min],1.5,99007,DB00381,Amlodipine
,20733043,C(min),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],3.80,100293,DB00381,Amlodipine
,20733043,C(max),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],14.70,100294,DB00381,Amlodipine
,20733043,AUC(24),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[h·mg] / [l],196.08,100295,DB00381,Amlodipine
≥,20733043,C(min),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],2,100296,DB00381,Amlodipine
>,20733043,AUC(24)/MIC(90) ratio,"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),,80,100297,DB00381,Amlodipine
≥,20733043,C(min),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],10,100298,DB00381,Amlodipine
≥,20733043,AUC(24),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[h·mg] / [l],400,100299,DB00381,Amlodipine
,2977393,Half lives,"Half lives were 31.2, 33 and 36.8 hours for 2.5, 5 and 10 mg respectively.",Amlodipine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977393/),h,31.2,104994,DB00381,Amlodipine
,2977393,Half lives,"Half lives were 31.2, 33 and 36.8 hours for 2.5, 5 and 10 mg respectively.",Amlodipine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977393/),h,33,104995,DB00381,Amlodipine
,2977393,Half lives,"Half lives were 31.2, 33 and 36.8 hours for 2.5, 5 and 10 mg respectively.",Amlodipine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977393/),h,36.8,104996,DB00381,Amlodipine
,1532771,bioavailability,"Following oral administration, bioavailability is 60 to 65% and plasma concentrations rise gradually to peak 6 to 8h after administration.",Clinical pharmacokinetics of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),%,60 to 65,105309,DB00381,Amlodipine
,1532771,terminal elimination half-life,Amlodipine is extensively metabolised in the liver (but there is no significant presystemic or first-pass metabolism) and is slowly cleared with a terminal elimination half-life of 40 to 50h.,Clinical pharmacokinetics of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),h,40 to 50,105310,DB00381,Amlodipine
,1532771,Volume of distribution,Volume of distribution is large (21 L/kg) and there is a high degree of protein binding (98%).,Clinical pharmacokinetics of amlodipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),[l] / [kg],21,105311,DB00381,Amlodipine
,1532771,protein binding,Volume of distribution is large (21 L/kg) and there is a high degree of protein binding (98%).,Clinical pharmacokinetics of amlodipine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),%,98,105312,DB00381,Amlodipine
,7867683,AUC (0-4 h),"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],161,105857,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],140,105858,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,168,105859,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,149,105860,DB00381,Amlodipine
,7867683,Tmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,149,105861,DB00381,Amlodipine
,7867683,AUC (0-24 h),"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],1470,105862,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],1410,105863,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,292,105864,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,257,105865,DB00381,Amlodipine
,7867683,Tmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,292,105866,DB00381,Amlodipine
,7867683,Tmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,257,105867,DB00381,Amlodipine
,7867683,AUC (0-144 h),"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],118,105868,DB00381,Amlodipine
,7867683,AUC (0-144 h),"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],114,105869,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],114,105870,DB00381,Amlodipine
,7867683,Cmax,"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,2.5,105871,DB00381,Amlodipine
,7867683,Tmax,"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,2.3,105872,DB00381,Amlodipine
,29498757,flow rate,"Ammonium formate and acetonitrile, pumped isocraticaly at a flow rate of 0.25 mL/min, were used as a mobile phase.",Quantification of amlodipine and atorvastatin in human plasma by UPLC-MS/MS method and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498757/),[ml] / [min],0.25,108282,DB00381,Amlodipine
<,29498757,run time,"A short run time, of <1.5 min, permits analysis of a large number of plasma samples per batch.",Quantification of amlodipine and atorvastatin in human plasma by UPLC-MS/MS method and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498757/),min,1.5,108283,DB00381,Amlodipine
,16084849,area under the curve from 0 to 24 hours (AUC),"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],122,109911,DB00381,Amlodipine
,16084849,area under the curve from 0 to 24 hours (AUC),"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],230,109912,DB00381,Amlodipine
,16084849,AUC,"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],800,109913,DB00381,Amlodipine
,17803059,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 6,183.7 pg/ml (test) and 5,366.7 pg/ml (reference) were achieved.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[pg] / [ml],"6,183.7",110620,DB00381,Amlodipine
,17803059,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 6,183.7 pg/ml (test) and 5,366.7 pg/ml (reference) were achieved.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[pg] / [ml],"5,366.7",110621,DB00381,Amlodipine
,17803059,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 267,231.0 pg x h/ml (test) and 266,061.7 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[h·pg] / [ml],"267,231.0",110622,DB00381,Amlodipine
,17803059,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 267,231.0 pg x h/ml (test) and 266,061.7 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[h·ng] / [ml],"266,061.7",110623,DB00381,Amlodipine
,17803059,tmax,The median tmax was 5.6 h (test) and 6.1 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,5.6,110624,DB00381,Amlodipine
,17803059,tmax,The median tmax was 5.6 h (test) and 6.1 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,6.1,110625,DB00381,Amlodipine
,17803059,Plasma elimination half-lives (t 1/2),Plasma elimination half-lives (t 1/2) were 46.46 h (test) and 45.34 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,46.46,110626,DB00381,Amlodipine
,17803059,Plasma elimination half-lives (t 1/2),Plasma elimination half-lives (t 1/2) were 46.46 h (test) and 45.34 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,45.34,110627,DB00381,Amlodipine
,14501869,AUC(0-2),"In contrast, the combination of amlodipine significantly increased CsA AUC(0-2)/dose/kg (706.2 microg x hr/L to 819.2 microg x hr/L, P<0.05).","Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14501869/),[h·μg] / [l],706.2,115163,DB00381,Amlodipine
,14501869,AUC(0-2),"In contrast, the combination of amlodipine significantly increased CsA AUC(0-2)/dose/kg (706.2 microg x hr/L to 819.2 microg x hr/L, P<0.05).","Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14501869/),[h·μg] / [l],819.2,115164,DB00381,Amlodipine
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],4.95,117619,DB00381,Amlodipine
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],8.71,117620,DB00381,Amlodipine
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],12.48,117621,DB00381,Amlodipine
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],1.69,117622,DB00381,Amlodipine
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],3.89,117623,DB00381,Amlodipine
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],7.17,117624,DB00381,Amlodipine
,10516936,trough levels (C24 h),"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[ng] / [ml],22.8,118072,DB00381,Amlodipine
,10516936,trough levels (C24 h),"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[ng] / [ml],49.5,118073,DB00381,Amlodipine
,10516936,AUC,"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[hng] / [ml],1134.4,118074,DB00381,Amlodipine
,10516936,AUC,"Mean PK parameters in the rapid versus slow transit group were the following: trough levels (C24 h): 22.8 +/- 8.3 versus 49.5 +/- 35.7 ng/ml, p < 0.05; AUC 1134.4 +/- 512.7 versus 1704.7 +/- 1185.6 hng/ml, p < 0.05 (one-sided).",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),[hng] / [ml],1704.7,118075,DB00381,Amlodipine
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,1.8,118076,DB00381,Amlodipine
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,7.6,118077,DB00381,Amlodipine
,10516936,Peak-to-trough ratios (Cmax/C24 h,"Peak-to-trough ratios (Cmax/C24 h mean) were 1.8 +/- 0.9 for DIL, 7.6 +/- 3.5 for FEL, and 1.7 +/- 0.2 for AML.",The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516936/),,1.7,118078,DB00381,Amlodipine
,1534713,oral bioavailability,It has high oral bioavailability (60-80%) and accumulates to a steady-state with once-daily administration over a period of 1-1 1/2 weeks.,Pharmacokinetics and pharmacodynamics of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1534713/),%,60-80,118229,DB00381,Amlodipine
,17190374,AUC0-infinity,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[h·ng] / [ml],190.91,122461,DB00381,Amlodipine
,17190374,AUC0-infinity,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[h·ng] / [ml],203.15,122462,DB00381,Amlodipine
,17190374,Cmax,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[ng] / [ml],3.87,122463,DB00381,Amlodipine
,17190374,Cmax,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[ng] / [ml],4.01,122464,DB00381,Amlodipine
,32727577,half-life,"Study 1: esaxerenone peak plasma concentration (Cmax) and time to Cmax were unaltered by amlodipine coadministration, but mean half-life was slightly prolonged from 18.5 to 20.9 h.",Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32727577/),h,18,122698,DB00381,Amlodipine
,32727577,half-life,"Study 1: esaxerenone peak plasma concentration (Cmax) and time to Cmax were unaltered by amlodipine coadministration, but mean half-life was slightly prolonged from 18.5 to 20.9 h.",Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32727577/),h,20,122699,DB00381,Amlodipine
,30713247,milk/plasma concentration ratio,"5) In breastfeeding women, the median milk/plasma concentration ratio of amlodipine was 0.85.",Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713247/),,0.85,123684,DB00381,Amlodipine
,16413246,CL/F,The mean CL/F was 7.83 +/- 0.50 mL.min(-1).kg(-1) (LBW) in women compared with 6.31 +/- 1.01 in men and 8.68 +/- 1.00 mL.min(-1).,Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413246/),[ml] / [kg·min],7.83,126414,DB00381,Amlodipine
,16413246,CL/F,The mean CL/F was 7.83 +/- 0.50 mL.min(-1).kg(-1) (LBW) in women compared with 6.31 +/- 1.01 in men and 8.68 +/- 1.00 mL.min(-1).,Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413246/),[ml] / [min],6.31,126415,DB00381,Amlodipine
,16413246,CL/F,The mean CL/F was 7.83 +/- 0.50 mL.min(-1).kg(-1) (LBW) in women compared with 6.31 +/- 1.01 in men and 8.68 +/- 1.00 mL.min(-1).,Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413246/),[ml] / [min],8.68,126416,DB00381,Amlodipine
,19813460,flow rate,"The mobile phase was 10 mmol/L ammonium acetate solution-methanol (30:70, v/v) at the flow rate of 0.2 mL/min.",Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813460/),[ml] / [min],0.2,128543,DB00381,Amlodipine
,19813460,relative bioavailability,The relative bioavailability was 103.7 +/- 12.3%.,Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813460/),%,103.7,128544,DB00381,Amlodipine
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB00381,Amlodipine
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB00381,Amlodipine
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB00381,Amlodipine
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB00381,Amlodipine
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB00381,Amlodipine
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],5.234,129263,DB00381,Amlodipine
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],4.991,129264,DB00381,Amlodipine
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],108.839,129265,DB00381,Amlodipine
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],114.783,129266,DB00381,Amlodipine
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],97.814,129267,DB00381,Amlodipine
,23471702,Cmax,"Test and reference formulations gave a mean Cmax of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[ng] / [ml],93.731,129268,DB00381,Amlodipine
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],161.484,129269,DB00381,Amlodipine
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],1 917.644,129270,DB00381,Amlodipine
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],822.847,129271,DB00381,Amlodipine
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],162.108,129272,DB00381,Amlodipine
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],2 014.764,129273,DB00381,Amlodipine
,23471702,AUC0-t,"The AUC0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.",A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471702/),[h·ng] / [ml],829.323,129274,DB00381,Amlodipine
,1840130,retention times,"Under these conditions, the retention times of amlodipine and the internal standard desipramine were 10.6 and 12.9 min, respectively.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),min,10.6,130413,DB00381,Amlodipine
,1840130,retention times,"Under these conditions, the retention times of amlodipine and the internal standard desipramine were 10.6 and 12.9 min, respectively.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),min,12.9,130414,DB00381,Amlodipine
,1840130,sensitivity,"Using 1 ml of plasma, sensitivity of the assay was 2.5 ng ml-1 at which the RSD was 11%.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[ng] / [ml],2.5,130415,DB00381,Amlodipine
,1840130,half-life (t1/2),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),h,6.5,130416,DB00381,Amlodipine
,1840130,systemic clearance (CL),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[l] / [h·kg],4.8,130417,DB00381,Amlodipine
,1840130,apparent volume of distribution at steady state (Vdss),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[l] / [kg],30.2,130418,DB00381,Amlodipine
,2467131,elimination half-life,"The elimination half-life was of the order of 50 h, similar to previously observed values, and did not vary with differences in renal function.",Pharmacokinetics of amlodipine in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467131/),h,50,133739,DB00381,Amlodipine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB00381,Amlodipine
,2967593,oral bioavailability,The drug was well absorbed by the oral route while the mean oral bioavailability for unchanged drug was 62.5%.,Metabolism and kinetics of amlodipine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),%,62.5,135374,DB00381,Amlodipine
,2967593,total recovered radioactivity,Mean total recovered radioactivity in urine and faeces amounted to 84% for both the oral and intravenous routes.,Metabolism and kinetics of amlodipine in man. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),%,84,135375,DB00381,Amlodipine
,2967593,half-life,"4. For the two volunteers, amlodipine concentrations in plasma declined with a mean half-life of 33 h, while slower elimination of total drug-related material from plasma was observed, consistent with prolonged excretion (up to 12 days) of metabolites in urine and faeces.",Metabolism and kinetics of amlodipine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),h,33,135376,DB00381,Amlodipine
up to,2967593,excretion,"4. For the two volunteers, amlodipine concentrations in plasma declined with a mean half-life of 33 h, while slower elimination of total drug-related material from plasma was observed, consistent with prolonged excretion (up to 12 days) of metabolites in urine and faeces.",Metabolism and kinetics of amlodipine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),d,12,135377,DB00381,Amlodipine
,2530866,absolute bioavailability,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,64,140280,DB00381,Amlodipine
,2530866,elimination half-life,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140281,DB00381,Amlodipine
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 10,140282,DB00381,Amlodipine
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,10,140283,DB00381,Amlodipine
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,30,140284,DB00381,Amlodipine
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 6,140285,DB00381,Amlodipine
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,48,140286,DB00381,Amlodipine
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,35,140287,DB00381,Amlodipine
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,60,140288,DB00381,Amlodipine
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140289,DB00381,Amlodipine
,17213004,Cmax AUC from time 0 to the last available measurement (AUC(last)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[ng] / [ml],3.0,141563,DB00381,Amlodipine
,17213004,Cmax AUC from time 0 to the last available measurement (AUC(last)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],151.4,141564,DB00381,Amlodipine
,17213004,Cmax AUC from time 0 to the last available measurement (AUC(last)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[ng] / [ml],3.1,141565,DB00381,Amlodipine
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],175.3,141566,DB00381,Amlodipine
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[ng] / [ml],3.1,141567,DB00381,Amlodipine
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],139.7,141568,DB00381,Amlodipine
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],161.7,141569,DB00381,Amlodipine
,29604332,time to reach peak (Tmax),"In addition, there was an increasing trend in time to reach peak (Tmax) of VAL in FDCs, where it was increased by 0.22-0.34 h in mean and 0.40-0.44 h in median, except the combination of VAL/HCT at 160/12.5 mg.",Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604332/),h,0.22-0.34,141590,DB00381,Amlodipine
,29604332,time to reach peak (Tmax),"In addition, there was an increasing trend in time to reach peak (Tmax) of VAL in FDCs, where it was increased by 0.22-0.34 h in mean and 0.40-0.44 h in median, except the combination of VAL/HCT at 160/12.5 mg.",Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604332/),h,0.40-0.44,141591,DB00381,Amlodipine
,31852330,swelling index,"The swelling index and floating duration for the optimized formulation were 140.48 ± 0.57 and 8.53 ± 0.10 h, respectively.","Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852330/),h,140.48,142329,DB00381,Amlodipine
,31852330,floating duration,"The swelling index and floating duration for the optimized formulation were 140.48 ± 0.57 and 8.53 ± 0.10 h, respectively.","Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852330/),h,8.53,142330,DB00381,Amlodipine
,29523279,elimination half-life,"In the immediate postpartum period, the amlodipine elimination half-life was 13.7 ± 4.9 h, the area under the curve was 53.4 ± 19.8 ng*h/mL and the peak concentration was 2.0 ± 1.0 ng/mL.",Pharmacokinetics of amlodipine besylate at delivery and during lactation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29523279/),h,13.7,143375,DB00381,Amlodipine
,29523279,area under the curve,"In the immediate postpartum period, the amlodipine elimination half-life was 13.7 ± 4.9 h, the area under the curve was 53.4 ± 19.8 ng*h/mL and the peak concentration was 2.0 ± 1.0 ng/mL.",Pharmacokinetics of amlodipine besylate at delivery and during lactation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29523279/),[h·ng] / [ml],53.4,143376,DB00381,Amlodipine
,29523279,peak concentration,"In the immediate postpartum period, the amlodipine elimination half-life was 13.7 ± 4.9 h, the area under the curve was 53.4 ± 19.8 ng*h/mL and the peak concentration was 2.0 ± 1.0 ng/mL.",Pharmacokinetics of amlodipine besylate at delivery and during lactation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29523279/),[ng] / [ml],2.0,143377,DB00381,Amlodipine
,30182817,Cmax,"The results indicated that when the rats were pretreated with EGCG, the Cmax of amlodipine increased from 16.32 ± 2.57 to 21.44 ± 3.56 ng/mL (p < 0.05), the Tmax decreased from 5.98 ± 1.25 to 4.01 ± 1.02 h (p < 0.05), and the AUC0-t increased from 258.12 ± 76.25 to 383.34 ± 86.95 μg h L-1 (p < 0.05), which suggested that the pharmacokinetic behavior of amlodipine was affected after oral co-administration of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),[ng] / [ml],16.32,145971,DB00381,Amlodipine
,30182817,Cmax,"The results indicated that when the rats were pretreated with EGCG, the Cmax of amlodipine increased from 16.32 ± 2.57 to 21.44 ± 3.56 ng/mL (p < 0.05), the Tmax decreased from 5.98 ± 1.25 to 4.01 ± 1.02 h (p < 0.05), and the AUC0-t increased from 258.12 ± 76.25 to 383.34 ± 86.95 μg h L-1 (p < 0.05), which suggested that the pharmacokinetic behavior of amlodipine was affected after oral co-administration of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),[ng] / [ml],21.44,145972,DB00381,Amlodipine
,30182817,Tmax,"The results indicated that when the rats were pretreated with EGCG, the Cmax of amlodipine increased from 16.32 ± 2.57 to 21.44 ± 3.56 ng/mL (p < 0.05), the Tmax decreased from 5.98 ± 1.25 to 4.01 ± 1.02 h (p < 0.05), and the AUC0-t increased from 258.12 ± 76.25 to 383.34 ± 86.95 μg h L-1 (p < 0.05), which suggested that the pharmacokinetic behavior of amlodipine was affected after oral co-administration of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),h,5.98,145973,DB00381,Amlodipine
,30182817,Tmax,"The results indicated that when the rats were pretreated with EGCG, the Cmax of amlodipine increased from 16.32 ± 2.57 to 21.44 ± 3.56 ng/mL (p < 0.05), the Tmax decreased from 5.98 ± 1.25 to 4.01 ± 1.02 h (p < 0.05), and the AUC0-t increased from 258.12 ± 76.25 to 383.34 ± 86.95 μg h L-1 (p < 0.05), which suggested that the pharmacokinetic behavior of amlodipine was affected after oral co-administration of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),h,4.01,145974,DB00381,Amlodipine
,30182817,AUC0-t,"The results indicated that when the rats were pretreated with EGCG, the Cmax of amlodipine increased from 16.32 ± 2.57 to 21.44 ± 3.56 ng/mL (p < 0.05), the Tmax decreased from 5.98 ± 1.25 to 4.01 ± 1.02 h (p < 0.05), and the AUC0-t increased from 258.12 ± 76.25 to 383.34 ± 86.95 μg h L-1 (p < 0.05), which suggested that the pharmacokinetic behavior of amlodipine was affected after oral co-administration of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),[h·μg] / [l],258.12,145975,DB00381,Amlodipine
,30182817,AUC0-t,"The results indicated that when the rats were pretreated with EGCG, the Cmax of amlodipine increased from 16.32 ± 2.57 to 21.44 ± 3.56 ng/mL (p < 0.05), the Tmax decreased from 5.98 ± 1.25 to 4.01 ± 1.02 h (p < 0.05), and the AUC0-t increased from 258.12 ± 76.25 to 383.34 ± 86.95 μg h L-1 (p < 0.05), which suggested that the pharmacokinetic behavior of amlodipine was affected after oral co-administration of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),[h·μg] / [l],383.34,145976,DB00381,Amlodipine
,30182817,metabolic half-life,"Additionally, the metabolic half-life was prolonged from 31.3 ± 5.6 to 52.6 ± 7.9 min (p < 0.05) with the pretreatment of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),min,31.3,145977,DB00381,Amlodipine
,30182817,metabolic half-life,"Additionally, the metabolic half-life was prolonged from 31.3 ± 5.6 to 52.6 ± 7.9 min (p < 0.05) with the pretreatment of EGCG.",Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182817/),min,52.6,145978,DB00381,Amlodipine
,28976420,run time,The run time was 9 minutes.,Validated LC-MS/MS Method for the Simultaneous Determination of Amlodipine and Its Major Metabolites in Human Plasma of Hypertensive Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28976420/),min,9,146770,DB00381,Amlodipine
,28976420,extraction recovery rates,"Their extraction recovery rates and matrix factors in human plasma were 94.8%-109.0% and 97.0%-101.4%, respectively.",Validated LC-MS/MS Method for the Simultaneous Determination of Amlodipine and Its Major Metabolites in Human Plasma of Hypertensive Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28976420/),%,94.8,146771,DB00381,Amlodipine
,28976420,matrix factors,"Their extraction recovery rates and matrix factors in human plasma were 94.8%-109.0% and 97.0%-101.4%, respectively.",Validated LC-MS/MS Method for the Simultaneous Determination of Amlodipine and Its Major Metabolites in Human Plasma of Hypertensive Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28976420/),%,109,146772,DB00381,Amlodipine
,28976420,matrix factors,"Their extraction recovery rates and matrix factors in human plasma were 94.8%-109.0% and 97.0%-101.4%, respectively.",Validated LC-MS/MS Method for the Simultaneous Determination of Amlodipine and Its Major Metabolites in Human Plasma of Hypertensive Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28976420/),%,97.0,146773,DB00381,Amlodipine
,28976420,matrix factors,"Their extraction recovery rates and matrix factors in human plasma were 94.8%-109.0% and 97.0%-101.4%, respectively.",Validated LC-MS/MS Method for the Simultaneous Determination of Amlodipine and Its Major Metabolites in Human Plasma of Hypertensive Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28976420/),%,101.4,146774,DB00381,Amlodipine
,17516719,steady-state AUC,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],469,147595,DB00381,Amlodipine
,17516719,steady-state AUC,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],454,147596,DB00381,Amlodipine
,17516719,C(max),"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],96,147597,DB00381,Amlodipine
,17516719,C(max),"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],89,147598,DB00381,Amlodipine
,17516719,CL/F,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],197,147599,DB00381,Amlodipine
,17516719,CL/F,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],232,147600,DB00381,Amlodipine
,17516719,steady-state AUC,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],132,147601,DB00381,Amlodipine
,17516719,steady-state AUC,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],140,147602,DB00381,Amlodipine
,17516719,C(max),"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],7.1,147603,DB00381,Amlodipine
,17516719,C(max),"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],7.5,147604,DB00381,Amlodipine
,17516719,CL/F,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],41,147605,DB00381,Amlodipine
,17516719,CL/F,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],40,147606,DB00381,Amlodipine
,22993862,MPE,"MPE is 0.1% for scheme 6 and -0.6% for scheme 3, respectively.",[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993862/),%,0.1,150645,DB00381,Amlodipine
,22993862,MAPE,MAPE is 0.7% for both schemes.,[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993862/),,0,150646,DB00381,Amlodipine
,16855075,apparent clearances (CL/F),"For a subject at the population median weight (45 kg), predicted apparent clearances (CL/F) were 23.7 L/h for males and 17.6 L/h for females, and the apparent volume of distribution (V/F) was 25.1 L/kg.",Population pharmacokinetics of amlodipine in hypertensive children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855075/),[l] / [h],23.7,154425,DB00381,Amlodipine
,16855075,apparent clearances (CL/F),"For a subject at the population median weight (45 kg), predicted apparent clearances (CL/F) were 23.7 L/h for males and 17.6 L/h for females, and the apparent volume of distribution (V/F) was 25.1 L/kg.",Population pharmacokinetics of amlodipine in hypertensive children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855075/),[l] / [h],17.6,154426,DB00381,Amlodipine
,16855075,apparent volume of distribution (V/F),"For a subject at the population median weight (45 kg), predicted apparent clearances (CL/F) were 23.7 L/h for males and 17.6 L/h for females, and the apparent volume of distribution (V/F) was 25.1 L/kg.",Population pharmacokinetics of amlodipine in hypertensive children and adolescents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855075/),[l] / [kg],25.1,154427,DB00381,Amlodipine
,31058419,AUCτ,"Losartan did not influence the exposure of amlodipine at steady-state (AUCτ , 165.15 ng h/mL [amlodipine alone] vs 172.36 ng h/mL [combination], P = 0.389) [geometric mean ratio (GMR) (90% confidence interval [CI]), 1.060 (0.954-1.178)].",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],165.15,156995,DB00381,Amlodipine
,31058419,AUCτ,"Losartan did not influence the exposure of amlodipine at steady-state (AUCτ , 165.15 ng h/mL [amlodipine alone] vs 172.36 ng h/mL [combination], P = 0.389) [geometric mean ratio (GMR) (90% confidence interval [CI]), 1.060 (0.954-1.178)].",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],172.36,156996,DB00381,Amlodipine
,31058419,AUCτ,"In addition, the exposure of EXP-3174 was not affected by amlodipine (AUCτ , 1159.46 ng h/mL vs 1105.10 ng h/mL, P = 0.295) (GMR [90% CI], 0.957 [0.891-1.027]).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1159.46,156997,DB00381,Amlodipine
,31058419,AUCτ,"In addition, the exposure of EXP-3174 was not affected by amlodipine (AUCτ , 1159.46 ng h/mL vs 1105.10 ng h/mL, P = 0.295) (GMR [90% CI], 0.957 [0.891-1.027]).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1105.10,156998,DB00381,Amlodipine
,31058419,AUCτ,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1241.50,156999,DB00381,Amlodipine
,31058419,AUCτ,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1082.02,157000,DB00381,Amlodipine
,31058419,oral clearance,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[l] / [h],84.65,157001,DB00381,Amlodipine
,31058419,oral clearance,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[l] / [h],97.26,157002,DB00381,Amlodipine
,9646331,half-life,Pharmacokinetic analysis of drug accumulation showed one-compartment characteristics with an half-life of 76 min.,Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),min,76,157310,DB00381,Amlodipine
,9646331,phasic half-lives,"Whereas disposition exhibited two-compartment characteristics with phasic half-lives of 25 and 174 min., respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),min,25,157311,DB00381,Amlodipine
,9646331,phasic half-lives,"Whereas disposition exhibited two-compartment characteristics with phasic half-lives of 25 and 174 min., respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),min,174,157312,DB00381,Amlodipine
,9646331,Emax,Coronary flow-rate increased with an Emax of 119% and an EC50 of 1.2 x 10(-8) M.,Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),%,119,157313,DB00381,Amlodipine
,9646331,EC50,Coronary flow-rate increased with an Emax of 119% and an EC50 of 1.2 x 10(-8) M.,Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),M,1.2 x 10(-8),157314,DB00381,Amlodipine
,9646331,Emax,"Observed Emax-values and curve-fitted EC50-values were: 97, 97 and 94% and 1.10(-8), 7.7 x 10(-9) and 2.1 x 10(-8) M, respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),%,97,157315,DB00381,Amlodipine
,9646331,Emax,"Observed Emax-values and curve-fitted EC50-values were: 97, 97 and 94% and 1.10(-8), 7.7 x 10(-9) and 2.1 x 10(-8) M, respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),%,94,157316,DB00381,Amlodipine
,9646331,curve-fitted EC50,"Observed Emax-values and curve-fitted EC50-values were: 97, 97 and 94% and 1.10(-8), 7.7 x 10(-9) and 2.1 x 10(-8) M, respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),%,94,157317,DB00381,Amlodipine
,9646331,curve-fitted EC50,"Observed Emax-values and curve-fitted EC50-values were: 97, 97 and 94% and 1.10(-8), 7.7 x 10(-9) and 2.1 x 10(-8) M, respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),M,1.10(-8),157318,DB00381,Amlodipine
,9646331,curve-fitted EC50,"Observed Emax-values and curve-fitted EC50-values were: 97, 97 and 94% and 1.10(-8), 7.7 x 10(-9) and 2.1 x 10(-8) M, respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),M,7.7 x 10(-9),157319,DB00381,Amlodipine
,9646331,curve-fitted EC50,"Observed Emax-values and curve-fitted EC50-values were: 97, 97 and 94% and 1.10(-8), 7.7 x 10(-9) and 2.1 x 10(-8) M, respectively.",Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646331/),M,2.1 x 10(-8),157320,DB00381,Amlodipine
,11170235,detection limit,The assay was specific for the free form of amlodipine with a detection limit of 0.1 ng/ml and the intra- and interassay coefficient of variation ranged from 1.6-10.2%.,Enzyme linked immunosorbent assay for determination of amlodipine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11170235/),[ng] / [ml],0.1,165001,DB00381,Amlodipine
,31181484,flow rate,"The two analytes were extracted from plasma sample using acetonitrile-induced protein precipitation then separated on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column by gradient elution using 6 mM ammonium formate/0.1% formic acid and ACN at a flow rate 0.4 mL min-1.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ml] / [min],0.4,167338,DB00381,Amlodipine
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,492.1,167339,DB00381,Amlodipine
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,206,167340,DB00381,Amlodipine
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,482.1,167341,DB00381,Amlodipine
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,258.1,167342,DB00381,Amlodipine
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,409.2,167343,DB00381,Amlodipine
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.05,167344,DB00381,Amlodipine
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.07,167345,DB00381,Amlodipine
,22192643,tmax,"Following the single-dose oral administration of valsartan/amlodipine 80/5 mg, valsartan and amlodipine plasma concentrations reached peak levels at median tmax of 3 and 6 h, respectively.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,3,171076,DB00381,Amlodipine
,22192643,tmax,"Following the single-dose oral administration of valsartan/amlodipine 80/5 mg, valsartan and amlodipine plasma concentrations reached peak levels at median tmax of 3 and 6 h, respectively.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,6,171077,DB00381,Amlodipine
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,7.7,171078,DB00381,Amlodipine
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,8.6,171079,DB00381,Amlodipine
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,47,171080,DB00381,Amlodipine
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,45,171081,DB00381,Amlodipine
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,533.1,171132,DB00381,Amlodipine
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,216.1,171133,DB00381,Amlodipine
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,407.6,171134,DB00381,Amlodipine
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,73.7,171135,DB00381,Amlodipine
,1992115,IC50,"The preparation of 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5- (methoxycarbonyl)-6-methyl-1,4-dihydropyridine (2) is described, and its potent calcium antagonist activity on rat aorta (IC50 = 4 x 10(-9) M) and marked tissue selectivity in vitro for vascular smooth muscle over cardiac smooth muscle are established.","Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),M,4 x 10(-9),174995,DB00381,Amlodipine
,1992115,ED50,Compound 2 has excellent in vivo activity in the anesthetized dog (ED50 = 12 micrograms/kg for reduction of CVR) and a plasma half-life in the conscious dog of 7.2 h.,"Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),[μg] / [kg],12,174996,DB00381,Amlodipine
,1992115,plasma half-life,Compound 2 has excellent in vivo activity in the anesthetized dog (ED50 = 12 micrograms/kg for reduction of CVR) and a plasma half-life in the conscious dog of 7.2 h.,"Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),h,7.2,174997,DB00381,Amlodipine
,1992115,plasma clearance,The plasma clearance for 2 (9.6 mL/min/kg) is similar to that of amlodipine and is consistent with the extended 2-substituent hindering approach to the cytochrome P-450 enzyme responsible for oxidation of the DHP ring to the corresponding pyridine.,"Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1992115/),[ml] / [kg·min],9.6,174998,DB00381,Amlodipine
,18752284,peak plasma concentrations (Cmax),S-amlodipine showed 15% higher mean peak plasma concentrations (Cmax) in CYP3A5*1/*3 carriers (3.28 ng/ml) than CYP3A5*3/*3 carriers (2.85 ng/ml) (P = 0.194) and R-amlodipine also showed 21% higher Cmax in CYP3A5*1/*3 carriers (3.33 ng/ml) than CYP3A5*3/*3 carriers (2.75 ng/ml) (P = 0.114).,Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[ng] / [ml],3.28,175802,DB00381,Amlodipine
,18752284,peak plasma concentrations (Cmax),S-amlodipine showed 15% higher mean peak plasma concentrations (Cmax) in CYP3A5*1/*3 carriers (3.28 ng/ml) than CYP3A5*3/*3 carriers (2.85 ng/ml) (P = 0.194) and R-amlodipine also showed 21% higher Cmax in CYP3A5*1/*3 carriers (3.33 ng/ml) than CYP3A5*3/*3 carriers (2.75 ng/ml) (P = 0.114).,Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[ng] / [ml],2.85,175803,DB00381,Amlodipine
,18752284,Cmax,S-amlodipine showed 15% higher mean peak plasma concentrations (Cmax) in CYP3A5*1/*3 carriers (3.28 ng/ml) than CYP3A5*3/*3 carriers (2.85 ng/ml) (P = 0.194) and R-amlodipine also showed 21% higher Cmax in CYP3A5*1/*3 carriers (3.33 ng/ml) than CYP3A5*3/*3 carriers (2.75 ng/ml) (P = 0.114).,Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[ng] / [ml],3.33,175804,DB00381,Amlodipine
,18752284,Cmax,S-amlodipine showed 15% higher mean peak plasma concentrations (Cmax) in CYP3A5*1/*3 carriers (3.28 ng/ml) than CYP3A5*3/*3 carriers (2.85 ng/ml) (P = 0.194) and R-amlodipine also showed 21% higher Cmax in CYP3A5*1/*3 carriers (3.33 ng/ml) than CYP3A5*3/*3 carriers (2.75 ng/ml) (P = 0.114).,Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[ng] / [ml],2.75,175805,DB00381,Amlodipine
,18752284,area under the time versus concentration curve,"CYP3A5*1/*3 carriers also have 23 and 12% higher mean area under the time versus concentration curve of R-amlodipine and S-amlodipine than CYP3A5*3/*3 carriers, respectively (for R-amlodipine, 147.1 ng*h/ml for CYP3A5*1/*3 carriers versus 121.8 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.234; for S-amlodipine, 161.6 ng*h/ml for CYP3A5*1/*3 carriers vs. 144.2 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.353).",Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[h·ng] / [ml],147.1,175806,DB00381,Amlodipine
,18752284,area under the time versus concentration curve,"CYP3A5*1/*3 carriers also have 23 and 12% higher mean area under the time versus concentration curve of R-amlodipine and S-amlodipine than CYP3A5*3/*3 carriers, respectively (for R-amlodipine, 147.1 ng*h/ml for CYP3A5*1/*3 carriers versus 121.8 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.234; for S-amlodipine, 161.6 ng*h/ml for CYP3A5*1/*3 carriers vs. 144.2 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.353).",Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[h·ng] / [ml],121.8,175807,DB00381,Amlodipine
,18752284,area under the time versus concentration curve,"CYP3A5*1/*3 carriers also have 23 and 12% higher mean area under the time versus concentration curve of R-amlodipine and S-amlodipine than CYP3A5*3/*3 carriers, respectively (for R-amlodipine, 147.1 ng*h/ml for CYP3A5*1/*3 carriers versus 121.8 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.234; for S-amlodipine, 161.6 ng*h/ml for CYP3A5*1/*3 carriers vs. 144.2 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.353).",Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[h·ng] / [ml],161.6,175808,DB00381,Amlodipine
,18752284,area under the time versus concentration curve,"CYP3A5*1/*3 carriers also have 23 and 12% higher mean area under the time versus concentration curve of R-amlodipine and S-amlodipine than CYP3A5*3/*3 carriers, respectively (for R-amlodipine, 147.1 ng*h/ml for CYP3A5*1/*3 carriers versus 121.8 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.234; for S-amlodipine, 161.6 ng*h/ml for CYP3A5*1/*3 carriers vs. 144.2 ng*h/ml for CYP3A5*3/*3 carriers, P = 0.353).",Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752284/),[h·ng] / [ml],144.2,175809,DB00381,Amlodipine
,7760349,IC50,The permanently charged amlodipine derivative inhibited radioligand DHP binding in partially purified rabbit skeletal muscle transverse tubule membranes with a pseudo-Hill slope close to unity and an IC50 value of 4.2 +/- 0.6 microM.,Inhibition of cardiac L-type calcium channels by quaternary amlodipine: implications for pharmacokinetics and access to dihydropyridine binding site. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7760349/),μM,4.2,180310,DB00381,Amlodipine
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB00381,Amlodipine
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB00381,Amlodipine
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB00381,Amlodipine
,16038908,minimum detectable limit,The assay enables the measurement of amlodipine for therapeutic drug monitoring with a minimum detectable limit of 0.2 ng ml(-1).,Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16038908/),[ng] / [ml],0.2,186004,DB00381,Amlodipine
,16038908,analytical recovery,"The method involves simple, one-step extraction procedure and analytical recovery was about 97%.",Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16038908/),%,97,186005,DB00381,Amlodipine
,16038908,flow rate,"The mobile phase was a mixture of 0.01 M sodium dihydrogen phosphate buffer and acetonitrile (63:37, v/v) adjusted to pH 3.5 at a flow rate of 1.5 ml min(-1).",Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16038908/),[ml] / [min],1.5,186006,DB00381,Amlodipine
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2439,189018,DB00381,Amlodipine
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2388,189019,DB00381,Amlodipine
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2340,189020,DB00381,Amlodipine
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2247,189021,DB00381,Amlodipine
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],465.7,189022,DB00381,Amlodipine
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],439.5,189023,DB00381,Amlodipine
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],447.4,189024,DB00381,Amlodipine
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],423.8,189025,DB00381,Amlodipine
,19659504,t(max),Median t(max) values for olmesartan were 1.5 h for each group in each study.,Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),h,1.5,189026,DB00381,Amlodipine
,23369879,constant flow rate,"Adequate chromatographic separation was achieved using Phenomenex Synergi 4u polar-RP 80A (150mm×4.6mm, 4μm) column in the isocratic elution mode and the eluent was water/methanol (14:86%, v/v) adjusted by trichloroacetic acid to pH 3.2 which was delivered isocratically at constant flow rate of 0.50mL/min.",Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23369879/),[ml] / [min],0.50,189319,DB00381,Amlodipine
,17116433,retention times,"Perospirone and IS eluted as sharp, symmetrical peaks with retention times of 3.11+/-0.01min and 4.15+/-0.2min, respectively.",Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116433/),min,3.11,190904,DB00381,Amlodipine
,17116433,retention times,"Perospirone and IS eluted as sharp, symmetrical peaks with retention times of 3.11+/-0.01min and 4.15+/-0.2min, respectively.",Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116433/),min,4.15,190905,DB00381,Amlodipine
more,17116433,absolute recovery,The mean absolute recovery of the drug from plasma was more than 85%.,Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116433/),%,85,190906,DB00381,Amlodipine
,17116433,area under the plasma concentration versus time curve from time 0 to 24h (AUC(0-24)),The area under the plasma concentration versus time curve from time 0 to 24h (AUC(0-24)) was 15.48+/-4.23microg/Lh; peak plasma concentration (C(max)) was 2.79+/-0.78microg/L; time to C(max) (T(max)) was 1.79+/-0.45h; and elimination half-life (t(1/2)) 6.78+/-1.38h.,Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116433/),[μg] / [lh],15.48,190907,DB00381,Amlodipine
,17116433,peak plasma concentration (C(max)),The area under the plasma concentration versus time curve from time 0 to 24h (AUC(0-24)) was 15.48+/-4.23microg/Lh; peak plasma concentration (C(max)) was 2.79+/-0.78microg/L; time to C(max) (T(max)) was 1.79+/-0.45h; and elimination half-life (t(1/2)) 6.78+/-1.38h.,Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116433/),[μg] / [l],2.79,190908,DB00381,Amlodipine
,17116433,time to C(max) (T(max)),The area under the plasma concentration versus time curve from time 0 to 24h (AUC(0-24)) was 15.48+/-4.23microg/Lh; peak plasma concentration (C(max)) was 2.79+/-0.78microg/L; time to C(max) (T(max)) was 1.79+/-0.45h; and elimination half-life (t(1/2)) 6.78+/-1.38h.,Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116433/),h,1.79,190909,DB00381,Amlodipine
,17116433,elimination half-life (t(1/2)),The area under the plasma concentration versus time curve from time 0 to 24h (AUC(0-24)) was 15.48+/-4.23microg/Lh; peak plasma concentration (C(max)) was 2.79+/-0.78microg/L; time to C(max) (T(max)) was 1.79+/-0.45h; and elimination half-life (t(1/2)) 6.78+/-1.38h.,Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116433/),h,6.78,190910,DB00381,Amlodipine
,17803060,AUCt,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[h·ng] / [ml],353.15,194768,DB00381,Amlodipine
,17803060,AUCinf,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[h·ng] / [ml],417.86,194769,DB00381,Amlodipine
,17803060,Cmax,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[h·ng] / [ml],417.86,194770,DB00381,Amlodipine
,17803060,Cmax,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[ng] / [ml],8.08,194771,DB00381,Amlodipine
,17803060,t(1/2),"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,48.04,194772,DB00381,Amlodipine
,17803060,t(1/2),"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,43.81,194773,DB00381,Amlodipine
,17803060,Tmax,"The median Tmax of the test drug and reference drug were 8.0 h and 8.5 h, respectively.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,8.0,194774,DB00381,Amlodipine
,17803060,Tmax,"The median Tmax of the test drug and reference drug were 8.0 h and 8.5 h, respectively.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,8.5,194775,DB00381,Amlodipine
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,44,195599,DB00381,Amlodipine
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,32.2,195600,DB00381,Amlodipine
,32371763,entrapment efficiencies,"The entrapment efficiencies ranged from 44 ± 2.1, 32.2 ± 4 and 40.5 ± 2.6% for amlodipine, hydrochlorothiazide and CNDT, respectively.",Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32371763/),%,40.5,195601,DB00381,Amlodipine
,7986667,terminal half-lives,"(R)-Amlodipine was more rapidly eliminated from plasma than (S)-amlodipine, with mean terminal half-lives of 34.9 h (R) and 49.6 h (S).",Enantioselective disposition of oral amlodipine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986667/),h,34.9,196290,DB00381,Amlodipine
,7986667,terminal half-lives,"(R)-Amlodipine was more rapidly eliminated from plasma than (S)-amlodipine, with mean terminal half-lives of 34.9 h (R) and 49.6 h (S).",Enantioselective disposition of oral amlodipine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986667/),h,49.6,196291,DB00381,Amlodipine
,7986667,terminal half-lives,The terminal half-lives of total amlodipine (mean 44.2 h) were strongly correlated with--and thus highly predictive for--the half-lives of the (S)-enantiomer.,Enantioselective disposition of oral amlodipine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986667/),h,44.2,196292,DB00381,Amlodipine
,24522199,CL/F,The CL/F value in a male patient with the ABCB1 3435CC or CT genotype is 28.8 L/h.,ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24522199/),[l] / [h],28.8,196487,DB00381,Amlodipine
,2467133,elimination half-life,"After i.v. amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs. 48 +/- 8 h; mean +/- SD).",Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467133/),h,64,203993,DB00381,Amlodipine
,2467133,elimination half-life,"After i.v. amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs. 48 +/- 8 h; mean +/- SD).",Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467133/),h,48,203994,DB00381,Amlodipine
,26142429,flow rate,"The analytes and internal standard diphenhydramine were separated on a Zorbax SB-C18 column with a mobile phase of acetonitrile : water (45 : 55, v/v) at a flow rate of 0.2 mL/min with an operating temperature of 25°C.",Simultaneous determination of telmisartan and amlodipine in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26142429/),[ml] / [min],0.2,204922,DB00381,Amlodipine
>,26142429,recoveries,The average recoveries of analytes were >85.0%.,Simultaneous determination of telmisartan and amlodipine in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26142429/),%,85.0,204923,DB00381,Amlodipine
,23640924,total run time,"The total run time was 3.5 min and the elution of R-AML, S-AML, R-AML-d4 and S-AML-d4 occurred at 1.62, 2.51, 1.63 and 2.53 min, respectively.",Rapid quantification of amlodipine enantiomers in human plasma by LC-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23640924/),min,3.5,205098,DB00381,Amlodipine
,23640924,el,"The total run time was 3.5 min and the elution of R-AML, S-AML, R-AML-d4 and S-AML-d4 occurred at 1.62, 2.51, 1.63 and 2.53 min, respectively.",Rapid quantification of amlodipine enantiomers in human plasma by LC-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23640924/),min,1.62,205099,DB00381,Amlodipine
,23640924,el,"The total run time was 3.5 min and the elution of R-AML, S-AML, R-AML-d4 and S-AML-d4 occurred at 1.62, 2.51, 1.63 and 2.53 min, respectively.",Rapid quantification of amlodipine enantiomers in human plasma by LC-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23640924/),min,2.51,205100,DB00381,Amlodipine
,23640924,el,"The total run time was 3.5 min and the elution of R-AML, S-AML, R-AML-d4 and S-AML-d4 occurred at 1.62, 2.51, 1.63 and 2.53 min, respectively.",Rapid quantification of amlodipine enantiomers in human plasma by LC-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23640924/),min,1.63,205101,DB00381,Amlodipine
,23640924,el,"The total run time was 3.5 min and the elution of R-AML, S-AML, R-AML-d4 and S-AML-d4 occurred at 1.62, 2.51, 1.63 and 2.53 min, respectively.",Rapid quantification of amlodipine enantiomers in human plasma by LC-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23640924/),min,2.53,205102,DB00381,Amlodipine
,23640924,flow rate,"This was achieved with a mobile phase consisting of 0.2% ammonia-acetonitrile (20:80, v/v) at a flow rate of 1 mL/min on a Chiralcel OJ RH column.",Rapid quantification of amlodipine enantiomers in human plasma by LC-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23640924/),[ml] / [min],1,205103,DB00381,Amlodipine
,12675275,plasma half-life (t1/2),The pharmacokinetic results indicated that the plasma half-life (t1/2) of amlodipine was 38.5 +/- 19.8 h and that of azelnidipine was 8.68 +/- 1.33 h.,Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675275/),h,38.5,208778,DB00381,Amlodipine
,12675275,plasma half-life (t1/2),The pharmacokinetic results indicated that the plasma half-life (t1/2) of amlodipine was 38.5 +/- 19.8 h and that of azelnidipine was 8.68 +/- 1.33 h.,Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675275/),h,8.68,208779,DB00381,Amlodipine
,33314205,flow rate,"Ammonium acetate and methanol, pumped at a flow rate of 0.3 ml/min, were used as a mobile phase.","Determination of amlodipine, indapamide and perindopril in human plasma by a novel LC-MS/MS method: Application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314205/),[ml] / [min],0.3,212489,DB00381,Amlodipine
,34383955,AUC0-t,H. sabdariffa increased AUC0-t of amlodipine from 81.8 ± 14.7 to 125.0 ± 10.6 (ng h/mL).,Effect of Hibiscus sabdariffa and Zingiber officinale on pharmacokinetics and pharmacodynamics of amlodipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34383955/),[h·ng] / [ml],81.8,212504,DB00381,Amlodipine
,34383955,AUC0-t,H. sabdariffa increased AUC0-t of amlodipine from 81.8 ± 14.7 to 125.0 ± 10.6 (ng h/mL).,Effect of Hibiscus sabdariffa and Zingiber officinale on pharmacokinetics and pharmacodynamics of amlodipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34383955/),[h·ng] / [ml],125.0,212505,DB00381,Amlodipine
,28535452,flow rate,The chromatographic resolution was achieved on a BEH C18 column using a gradient mobile phase consisting of 0.1% formic acid in water and acetonitrile with 0.1% formic acid at flow rate of 0.6mL/min.,Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ml] / [min],0.6,212955,DB00381,Amlodipine
,28535452,Total run time of analysis,"Total run time of analysis was 1.1min and elution of PF, 5-OHPF, N-DPF and I.S. occurred at 0.69, 0.6, 0.68 and 0.73min, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),min,1.1,212956,DB00381,Amlodipine
,28535452,AUC0-∞,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],6057,212957,DB00381,Amlodipine
,28535452,AUC0-∞,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],2002,212958,DB00381,Amlodipine
,28535452,AUC0-∞,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ng] / [ml],653,212959,DB00381,Amlodipine
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],2002,212960,DB00381,Amlodipine
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],525,212961,DB00381,Amlodipine
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ng] / [ml],295,212962,DB00381,Amlodipine
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ng] / [ml],68.4,212963,DB00381,Amlodipine
,10405773,plasma half-life,"The plasma half-life of amlodipine is as long as 36 h, while that of nitrendipine is 10 h.","Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10405773/),h,36,216029,DB00381,Amlodipine
,10405773,plasma half-life,"The plasma half-life of amlodipine is as long as 36 h, while that of nitrendipine is 10 h.","Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10405773/),h,10,216030,DB00381,Amlodipine
,29403761,flow rate,"The reconstituted samples were chromatographed on a Hypurity advance C18 column (50 mm×4.6 mm, 5 μm) using a mixture of acetonitrile-5 mM ammonium acetate buffer (pH-4.0) (50:50, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",Simultaneous determination of telmisartan and amlodipine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403761/),[ml] / [min],0.8,219051,DB00381,Amlodipine
,29403761,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Simultaneous determination of telmisartan and amlodipine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403761/),min,2.5,219052,DB00381,Amlodipine
,2524389,elimination half-life,"The elimination half-life was of the order of 50 h, similar to previously reported values and did not vary with renal function.",Pharmacokinetics of amlodipine in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524389/),h,50,219535,DB00381,Amlodipine
,19309765,flow rate,"Chromatographic separation was achieved with 10 mM ammonium acetate (pH 6.4): acetonitrile (15:85, v/v) at a flow rate of 0.50 mL/min on a Discovery HS C(18) column with a total run time of 3.5 min.","Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),[ml] / [min],0.50,220939,DB00381,Amlodipine
,19309765,total run time,"Chromatographic separation was achieved with 10 mM ammonium acetate (pH 6.4): acetonitrile (15:85, v/v) at a flow rate of 0.50 mL/min on a Discovery HS C(18) column with a total run time of 3.5 min.","Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),min,3.5,220940,DB00381,Amlodipine
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,586.10,220941,DB00381,Amlodipine
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,422.10,220942,DB00381,Amlodipine
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,409.20,220943,DB00381,Amlodipine
,19309765,ion transitions,The MS/MS ion transitions monitored were 586.10 --> 422.10 for MTK and 409.20 --> 238.30 for IS.,"Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309765/),,238.30,220944,DB00381,Amlodipine
,8009887,apparent liver volume,The apparent liver volume for amlodipine was 920 ml compared with 38ml for nitrendipine.,Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009887/),ml,920,223996,DB00381,Amlodipine
,8009887,apparent liver volume,The apparent liver volume for amlodipine was 920 ml compared with 38ml for nitrendipine.,Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009887/),ml,38,223997,DB00381,Amlodipine
,19930795,flow-rate,The flow-rate was 1.8 mL/min.,High-performance liquid chromatographic method for quantitative determination of amlodipine in human plasma and pharmaceutical dosage form and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930795/),[ml] / [min],1.8,228188,DB00381,Amlodipine
,19930795,limit of,"The limit of detection was 1.0 ng/mL, and the limit of quantification of amlodipine besylate in plasma was 10 ng/mL.",High-performance liquid chromatographic method for quantitative determination of amlodipine in human plasma and pharmaceutical dosage form and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930795/),[ng] / [ml],1.0,228189,DB00381,Amlodipine
,19930795,absolute,"The averages of the absolute and relative recoveries were found to be 96.74-98.51% and 95.96-100.71%, respectively.",High-performance liquid chromatographic method for quantitative determination of amlodipine in human plasma and pharmaceutical dosage form and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930795/),%,96.74-98.51,228190,DB00381,Amlodipine
,19930795,relative recoveries,"The averages of the absolute and relative recoveries were found to be 96.74-98.51% and 95.96-100.71%, respectively.",High-performance liquid chromatographic method for quantitative determination of amlodipine in human plasma and pharmaceutical dosage form and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930795/),%,95.96-100.71,228191,DB00381,Amlodipine
,23781473,flow rate,"The reconstituted samples were chromatographed on a C18 column by using an 85:15, v/v mixture of methanol and 0.1% v/v formic acid as the mobile phase at a flow rate of 1.0 mL/min.","Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781473/),[ml] / [min],1.0,230210,DB00381,Amlodipine
,23781473,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,"Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781473/),min,2.5,230211,DB00381,Amlodipine
,29860181,flow rate,"Stereoselective separation was performed on CHIRALCEL OZ-RH column (150 mm × 4.6 mm i.d., 5 μm) with acetonitrile-water (10 mM ammonium acetate, 0.5% ammonia solution) (95:5, v/v) at a flow rate of 0.5 mL/min.",Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),[ml] / [min],0.5,233363,DB00381,Amlodipine
,29860181,m/,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,409.1,233364,DB00381,Amlodipine
,29860181,m/,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,238.0,233365,DB00381,Amlodipine
,29860181,m/z,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,237.0,233366,DB00381,Amlodipine
,29860181,m/z,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,194.1,233367,DB00381,Amlodipine
excess of,28352156,radial crushing strength,ODTs containing amlodipine (5 mg) and atorvastatin (10 mg) either alone or in combination rapidly disintegrated (<30 s) while displaying a radial crushing strength in excess of 100 N and friability ≤1%.,"Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28352156/),n,100,235923,DB00381,Amlodipine
≤,28352156,friability,ODTs containing amlodipine (5 mg) and atorvastatin (10 mg) either alone or in combination rapidly disintegrated (<30 s) while displaying a radial crushing strength in excess of 100 N and friability ≤1%.,"Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28352156/),%,1,235924,DB00381,Amlodipine
,9401833,peak-to-trough plasma concentration ratio,"After repeated dosing the peak-to-trough plasma concentration ratio were 1.58 and 4.43 (p < 0.001) for amlodipine and felodipine ER, respectively.",Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401833/),,1.58,240501,DB00381,Amlodipine
,9401833,peak-to-trough plasma concentration ratio,"After repeated dosing the peak-to-trough plasma concentration ratio were 1.58 and 4.43 (p < 0.001) for amlodipine and felodipine ER, respectively.",Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401833/),,4.43,240502,DB00381,Amlodipine
,12845505,Cmax,"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),[μg] / [l],3.83,241139,DB00381,Amlodipine
,12845505,tmax,"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),,5.01,241140,DB00381,Amlodipine
,12845505,AUC(0-24),"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),[h·μg] / [l],59.90,241141,DB00381,Amlodipine
,12845505,kel,"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),1/[h],0.0177,241142,DB00381,Amlodipine
,12845505,accumulation index,The mean accumulation index on the basis of AUC(0-24) was calculated as 3.70.,Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),,3.70,241143,DB00381,Amlodipine
,17178265,oral clearance,"The difference in the oral clearance of amlodipine approached statistical significance between the 2 major genotype groups, with CYP3A5*1 carriers (27.0 +/- 8.2 L/h) showing 20% lower clearance than CYP3A5*3/*3 carriers (32.4 +/- 10.2 L/h) (P = .063).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[l] / [h],27.0,242101,DB00381,Amlodipine
,17178265,area under the plasma concentration-time curve,"However, the mean area under the plasma concentration-time curve of amlodipine was 200.9 +/- 61.9 ng . h/mL for CYP3A5*1 carriers and 167.6 +/- 45.0 ng . h/mL for CYP3A5*3/*3 carriers (P = .029).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[h·ng] / [ml],200.9,242102,DB00381,Amlodipine
,17178265,area under the plasma concentration-time curve,"However, the mean area under the plasma concentration-time curve of amlodipine was 200.9 +/- 61.9 ng . h/mL for CYP3A5*1 carriers and 167.6 +/- 45.0 ng . h/mL for CYP3A5*3/*3 carriers (P = .029).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[h·ng] / [ml],167.6,242103,DB00381,Amlodipine
,17178265,peak plasma concentration,"Moreover, the peak plasma concentration was significantly higher in CYP3A5*1 carriers (3.8 +/- 1.1 ng/mL) than in CYP3A5*3/*3 carriers (3.1 +/- 0.8 ng/mL) (P = .037).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[ng] / [ml],3.8,242104,DB00381,Amlodipine
,17178265,peak plasma concentration,"Moreover, the peak plasma concentration was significantly higher in CYP3A5*1 carriers (3.8 +/- 1.1 ng/mL) than in CYP3A5*3/*3 carriers (3.1 +/- 0.8 ng/mL) (P = .037).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[ng] / [ml],3.1,242105,DB00381,Amlodipine
,2467132,elimination half-life,The principal findings were that the mean elimination half-life was 48 h and that peak plasma drug concentrations were not observed until 7 h after dosing.,A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467132/),h,48,247345,DB00381,Amlodipine
,2467132,terminal elimination half-life,"The terminal elimination half-life of 48 h in the elderly was significantly longer than that of 35 h in the young subjects and there was a correspondingly greater area under the curve in the elderly, by approximately 50%.",A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467132/),h,48,247346,DB00381,Amlodipine
,2467132,terminal elimination half-life,"The terminal elimination half-life of 48 h in the elderly was significantly longer than that of 35 h in the young subjects and there was a correspondingly greater area under the curve in the elderly, by approximately 50%.",A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467132/),h,35,247347,DB00381,Amlodipine
,19446150,visible detection,"The visible detection of the method was in the range of 0.2 to 32.0 ng/mL, and the lower limit of quantification for amlodipine was 0.2 ng/mL.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],0.2 to 32.0,248619,DB00381,Amlodipine
,19446150,C(max),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],5.46,248620,DB00381,Amlodipine
,19446150,T(max),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],5.88,248621,DB00381,Amlodipine
,19446150,T(max),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,7.70,248622,DB00381,Amlodipine
,19446150,AUC(0-t),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],5.88,248623,DB00381,Amlodipine
,19446150,AUC(0-t),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,7.70,248624,DB00381,Amlodipine
,19446150,AUC(0-infinity)),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [h·ml],284.56,248625,DB00381,Amlodipine
,19446150,AUC(0-infinity)),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [h·ml],331.37,248626,DB00381,Amlodipine
,19446150,AUC(0-infinity)),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [h·ml],358.74,248627,DB00381,Amlodipine
,19446150,t(1/2),The mean (SD) t(1/2) was 38.52 (10.51) hours for the test formulation and 38.75 (7.07) hours for the reference formulation.,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,38.52,248628,DB00381,Amlodipine
,19446150,t(1/2),The mean (SD) t(1/2) was 38.52 (10.51) hours for the test formulation and 38.75 (7.07) hours for the reference formulation.,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,38.75,248629,DB00381,Amlodipine
,19446150,relative bioavailability,The relative bioavailability of the test formulation was 90.9% by mean AUC(0-t) and 91.2% by mean AUC(0-infinity).,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),%,90.9,248630,DB00381,Amlodipine
,19446150,relative bioavailability,The relative bioavailability of the test formulation was 90.9% by mean AUC(0-t) and 91.2% by mean AUC(0-infinity).,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),%,91.2,248631,DB00381,Amlodipine
,21401341,relative bioavailability,The pharmacokinetics and biodistribution studies of the optimized radiolabeled formulation (99mTc-labeled) in mice (p.o.) demonstrated a relative bioavailability of 475% against AB suspension.,Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401341/),%,475,253646,DB00381,Amlodipine
,21401341,drug targeting index,"In almost all the tested organs, the uptake of AB from NE was significantly higher (p < 0.05) than AB suspension especially in heart with a drug targeting index of 44.1%, also confirming the efficacy of nanosized formulation at therapeutic site.",Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401341/),%,44.1,253647,DB00381,Amlodipine
,16777390,droplet size,Dispersing DE in distilled water formed an emulsion with a mean droplet size 1.4-fold larger than that of the homogenized amlodipine emulsion before spray-drying (0.24 +/- 0.30 microm versus 0.17 +/- 0.02 microm).,Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16777390/),μm,0.24,256274,DB00381,Amlodipine
,16777390,droplet size,Dispersing DE in distilled water formed an emulsion with a mean droplet size 1.4-fold larger than that of the homogenized amlodipine emulsion before spray-drying (0.24 +/- 0.30 microm versus 0.17 +/- 0.02 microm).,Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16777390/),μm,0.17,256275,DB00381,Amlodipine
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,268.2,262035,DB00381,Amlodipine
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,409.1,262036,DB00381,Amlodipine
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,413.1,262037,DB00381,Amlodipine
,29115741,m/,"Quantification was performed in multiple reaction monitoring mode with the transition m/z 372.1 → 316.1 for arotinolol, m/z 268.2 → 116.2 for metoprolol, m/z 409.1 → 238.1 for amlodipine and m/z 413.1 → 238.1 for (S)-amlodipine-d4.",High-throughput LC-MS/MS method with 96-well plate precipitation for the determination of arotinolol and amlodipine in a small volume of rat plasma: Application to a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115741/),,238.1,262038,DB00381,Amlodipine
,34079222,retention times,"The HPLC retention times of AML-B and SIM were 2.10 and 15.52 min, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),min,2.10,263398,DB00381,Amlodipine
,34079222,retention times,"The HPLC retention times of AML-B and SIM were 2.10 and 15.52 min, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),min,15.52,263399,DB00381,Amlodipine
,34079222,percent recoveries,Linearity for AML-B was 5.0-50 ng/mL and 0.01-2.0 µg/mL for SIM with percent recoveries of 92.85-101.53% and 94.51-117.75% for AML-B and SIM.,Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),%,92.85-101.53,263400,DB00381,Amlodipine
,34079222,percent recoveries,Linearity for AML-B was 5.0-50 ng/mL and 0.01-2.0 µg/mL for SIM with percent recoveries of 92.85-101.53% and 94.51-117.75% for AML-B and SIM.,Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),%,94.51-117.75,263401,DB00381,Amlodipine
,34079222,tmax,"The tmax values for AML-B and SIM were 12 and 6 h, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,12,263402,DB00381,Amlodipine
,34079222,tmax,"The tmax values for AML-B and SIM were 12 and 6 h, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,6,263403,DB00381,Amlodipine
,34079222,tlag,"AML-B was absorbed without any lag time (tlag) while tlag was 6.33 ± 0.81 h for SIM, thus met the study objective.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,6.33,263404,DB00381,Amlodipine
,15222726,elimination half-life (t1/2),The mean elimination half-life (t1/2) for the test (40 h) and the reference (44 h) were within the values previously reported.,Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,40,267120,DB00381,Amlodipine
,15222726,elimination half-life (t1/2),The mean elimination half-life (t1/2) for the test (40 h) and the reference (44 h) were within the values previously reported.,Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,44,267121,DB00381,Amlodipine
,15222726,tmax,"Although the tmax of the test (5 h) was faster than the reference (6 h), the mean (90% CI) of the AUC(0-infinity) and Cmax ratios Test/Reference were 0.91 (0.87-0.97) and 1.01 (0.93-1.09), respectively.",Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,5,267122,DB00381,Amlodipine
,15222726,tmax,"Although the tmax of the test (5 h) was faster than the reference (6 h), the mean (90% CI) of the AUC(0-infinity) and Cmax ratios Test/Reference were 0.91 (0.87-0.97) and 1.01 (0.93-1.09), respectively.",Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,6,267123,DB00381,Amlodipine
,2943898,elimination half-life,"One compound, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5- methoxycarbonyl-6-methyl-1,4-dihydropyridine (17, amlodipine) was found to be comparable in potency to nifedipine and to have an elimination half-life of 30 h in dogs.",Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943898/),h,30,268060,DB00381,Amlodipine
,2943898,Oral bioavailability,"Oral bioavailability approached 100%, and hemodynamic responses were gradual in onset and long-lasting in effect.",Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943898/),%,100,268061,DB00381,Amlodipine
,23836529,flow rate,"Chromatographic separation was performed on a Inertsil C18 column (150 mm × 4.6 mm, 5 µm) using isocratic elution by a mobile phase consisting of methanol/water (55:45) at a flow rate of 1.2 mL/min.",HPLC fluorescence method for the determination of nizatidine in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23836529/),[ml] / [min],1.2,270376,DB00381,Amlodipine
,32407268,Tmax,"There was no remarkable effect of any of these two herbs on Cmax, AUC0-t, Kel, and terminal elimination half-life of amlodipine, but fenugreek altered the Tmax of amlodipine significantly, from 2 ± 1.2h in control to 7.2 ± 1.7h in fenugreek treated group, probably by delaying the absorption.",Effect of Nigella sativa and Fenugreek on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32407268/),h,2,270620,DB00381,Amlodipine
,32407268,Tmax,"There was no remarkable effect of any of these two herbs on Cmax, AUC0-t, Kel, and terminal elimination half-life of amlodipine, but fenugreek altered the Tmax of amlodipine significantly, from 2 ± 1.2h in control to 7.2 ± 1.7h in fenugreek treated group, probably by delaying the absorption.",Effect of Nigella sativa and Fenugreek on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32407268/),h,7.2,270621,DB00381,Amlodipine
,19716871,absolute bioavailability,"After transdermal administration to rats, the absolute bioavailability was 88.8% for S-AM free base.",A drug-in-adhesive transdermal patch for S-amlodipine free base: in vitro and in vivo characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716871/),%,88.8,271236,DB00381,Amlodipine
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,30,271417,DB00381,Amlodipine
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,33.5,271418,DB00381,Amlodipine
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,32,271419,DB00381,Amlodipine
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,8.9 to 80.59,271420,DB00381,Amlodipine
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,11 to 69.20,271421,DB00381,Amlodipine
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,9 to 101.49,271422,DB00381,Amlodipine
